Document:

Exhibit 10.1

 Exhibit 10.1 
 LIPOSCIENCE, INC. 
 LOAN AND SECURITY AGREEMENT 

 This LOAN AND SECURITY AGREEMENT (the “Agreement”) is entered into as of February 7, 2008, by
and between Square 1 Bank (“Bank”) and LIPOSCIENCE, INC. (“Borrower”). 
 RECITALS 

Borrower wishes to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrower. This Agreement sets forth the terms on which
Bank will advance credit to Borrower, and Borrower will repay the amounts owing to Bank. 
 AGREEMENT 

The parties agree as follows: 
  

	 	1.	DEFINITIONS AND CONSTRUCTION. 

 1.1 Definitions. As used in this Agreement, all capitalized terms shall have the definitions set forth on Exhibit A. Any term used in the Code and not defined herein shall have the meaning given to
the term in the Code. 
 1.2 Accounting Terms. Any accounting term not specifically defined on
Exhibit A shall be construed in accordance with GAAP and all calculations shall be made in accordance with GAAP. The term “financial statements” shall include the accompanying notes and schedules. 

 

	 	2.	LOAN AND TERMS OF PAYMENT. 

 2.1 Credit Extensions. 
 (a) Promise to Pay.
Borrower promises to pay to Bank, in lawful money of the United States of America, the aggregate unpaid principal amount of all Credit Extensions made by Bank to Borrower, together with interest on the unpaid principal amount of such Credit
Extensions at rates in accordance with the terms hereof. 
 (b) Advances Under Revolving Line.

 (i) Amount. Subject to and upon the terms and conditions of this Agreement (1) Borrower
may request Advances in an aggregate outstanding principal amount not to exceed the lesser of (A) the Revolving Line or (B) the Borrowing Base, less any amounts outstanding under the Ancillary Services Sublimit, and (2) amounts
borrowed pursuant to this Section 2.1(b) may be repaid and reborrowed at any time prior to the Revolving Maturity Date, at which time all Advances under this Section 2.1(b) shall be immediately due and payable. Borrower may prepay any
Advances without penalty or premium. 
 (ii) Form of Request. Whenever Borrower desires an
Advance, Borrower will notify Bank by facsimile transmission, telephone or email no later than 5:30 p.m. Eastern time (4:30 p.m. Eastern time for wire transfers), on the Business Day that the Advance is to be made. Each such notification shall be
promptly confirmed by a Loan Advance/Paydown Request Form in substantially the form of Exhibit C. Bank is authorized to make Advances under this Agreement, based upon instructions received from a Responsible Officer or a designee of a Responsible
Officer, or without instructions if in Bank’s discretion such Advances are necessary to meet Obligations which have become due and remain unpaid. Bank shall be entitled to rely on any telephonic or email notice given by a person whom Bank
reasonably believes to be a Responsible Officer or a designee thereof, and Borrower shall indemnify and hold Bank harmless for any damages or loss suffered by Bank as a result of such reliance. Bank will credit the amount of Advances made under this
Section 2.1(b) to Borrower’s deposit account. 

  
 1. 

 (iii) Ancillary Services Sublimit. Subject to the
availability under the Revolving Line, at any time and from time to time from the date hereof through the Business Day immediately prior to the Revolving Maturity Date, Borrower may request the provision of Ancillary Services from Bank. The
aggregate limit of the Ancillary Services shall not exceed the Ancillary Services Sublimit, provided that availability under the Revolving Line shall be reduced by the aggregate limits of (i) any outstanding and undrawn amounts under all
Letters of Credit issued hereunder, (ii) corporate credit cards issued to Borrower, (iii) the total amount of any Automated Clearing House processing reserves, (iv) the greater of the FX Amount or the Foreign Exchange Reserve
Percentage, and (v) any other reserves taken by Bank in connection with other treasury management services requested by Borrower and approved by Bank. In addition, Bank may, in its sole discretion, charge as Advances any amounts for which Bank
becomes liable to third parties in connection with the provision of the Ancillary Services. The terms and conditions (including repayment and fees) of such Ancillary Services shall be subject to the terms and conditions of the Bank’s standard
forms of application and agreement for the applicable Ancillary Services, which Borrower hereby agrees to execute. 
 (iv) Collateralization of Obligations Extending Beyond Maturity. If Borrower has not secured to Bank’s satisfaction its obligations with respect to any Letters of Credit, Credit Card
Services, ACH origination services, or Foreign Exchange Contracts by the Revolving Maturity Date, then, effective as of such date, the balance in any deposit accounts held by Bank and the certificates of deposit or time deposit accounts issued by
Bank in Borrower’s name (and any interest paid thereon or proceeds thereof, including any amounts payable upon the maturity or liquidation of such certificates or accounts), shall automatically secure such obligations to the extent of the then
continuing or outstanding and undrawn Letters of Credit, Credit Card Services, ACH origination services, or Foreign Exchange Contracts. Borrower authorizes Bank to hold such balances in pledge and to decline to honor any drafts thereon or any
requests by Borrower or any other Person to pay or otherwise transfer any part of such balances for so long as the Letters of Credit, Credit Card Services, ACH origination services, or Foreign Exchange Contracts are outstanding or continue.

 (c) Term Loan. 

(i) Subject to and upon the terms and conditions of this Agreement, Bank agrees to make Term Advances to Borrower
in two tranches, Tranche A and Tranche B. Borrower may request Term Advances under Tranche A at any time from the date hereof through the Tranche A Availability End Date. Borrower may request Term Advances under Tranche B at any time from the
Tranche A Availability End Date through the Tranche B Availability End Date. The aggregate outstanding amount of Tranche A Term Advances and Tranche B Term Advances shall not exceed the Term Loan. 

(ii) Interest shall accrue from the date of each Term Advance at the rate specified in Section 2.3(a), and
prior to the Availability End Date for the applicable Tranche shall be payable monthly beginning on the 7th day of the month next following the initial Term Advance for such Tranche, and continuing on the same day of each month therereafter. Any
Term Advances that are outstanding under Tranche A on the Tranche A Availability End Date shall be payable in 36 equal monthly installments of principal, plus all accrued interest, beginning on September 7, 2008, and continuing on the same day
of each month thereafter through the Term Loan Maturity Date, at which time all amounts due in connection with Tranche A Term Advance made under this Section 2.1(c) shall be immediately due and payable. Any Term Advances that are outstanding
under Tranche B on the Tranche B Availability End Date shall be payable in 30 equal monthly installments of principal, plus all accrued interest, beginning on March 7, 2009, and continuing on the same day of each month thereafter through the
Term Loan Maturity Date, at which time all amounts due in connection with Tranche B Term Advance made under this Section 2.1(c) and any other amounts due under this Agreement shall be immediately due and payable. Term Advances, once repaid, may
not be reborrowed. Borrower may prepay any Term Advances without penalty or premium. 
 (iii) When
Borrower desires to obtain a Term Advance, Borrower shall notify Bank (which notice shall be irrevocable) by facsimile transmission to be received no later than 3:00 p.m. Eastern time on the Business Day before the day on which the Term Advance is
to be made. Such notice shall be substantially in the form of Exhibit C. The notice shall be signed by a Responsible Officer or its designee. 

  
 2. 

 (iv) Notwithstanding any provision herein to the contrary, upon the
failure of Borrower to meet any of the milestone covenants set forth in Section 6.8, Borrower shall not request a Term Advance under Tranche B, and Bank shall not be obligated to make any Term Advance to Borrower, unless and until such
milestone covenant is satisfied in accordance with Section 6.8. 
 2.2 Overadvances. If the
aggregate amount of the outstanding Advances (including the Ancillary Services Sublimit) exceeds the lesser of the Revolving Line or the Borrowing Base at any time, Borrower shall immediately pay to Bank, in cash, the amount of such excess.

 2.3 Interest Rates, Payments, and Calculations. 

(a) Interest Rates. 

(i) Advances. Except as set forth in Section 2.3(b), the Advances shall bear interest, on the
outstanding daily balance thereof, at a variable annual rate equal to 1.0% above the Prime Rate then in effect. 

(ii) Term Loans. Except as set forth in Section 2.3(b), the Term Loans shall bear interest, on the
outstanding daily balance thereof, at a variable rate equal to 1.5% above the Prime Rate then in effect on the date of each such Term Loan. 
 (b) Late Fee; Default Rate. If any payment is not made within 10 Business Days after the date such payment is due, Borrower shall pay Bank a late fee equal to the lesser of (i) 5% of
the amount of such unpaid amount or (ii) the maximum amount permitted to be charged under applicable law. All Obligations shall bear interest, from and after the occurrence and during the continuance of an Event of Default, at a rate equal to 5
percentage points above the interest rate applicable immediately prior to the occurrence of the Event of Default. 
 (c) Payments. Interest under the Revolving Line shall be due and payable on the 7th calendar day of each month during the term hereof. Bank shall, at its option, charge such interest, all
Bank Expenses, and all Periodic Payments against any of Borrower’s deposit accounts or against the Revolving Line, in which case those amounts shall thereafter accrue interest at the rate then applicable hereunder. Any interest not paid when
due shall be compounded by becoming a part of the Obligations, and such interest shall thereafter accrue interest at the rate then applicable hereunder. 
 (d) Computation. In the event the Prime Rate is changed from time to time hereafter, the applicable rate of interest hereunder shall be increased or decreased, effective as of the day the
Prime Rate is changed, by an amount equal to such change in the Prime Rate. All interest chargeable under the Loan Documents shall be computed on the basis of a 360 day year for the actual number of days elapsed. 

2.4 Crediting Payments. Prior to the occurrence of an Event of Default, Bank shall credit a wire transfer of
funds, check or other item of payment to such deposit account or Obligation as Borrower specifies. After the occurrence and during the continuance of an Event of Default, Bank shall have the right, in its sole discretion, to immediately apply any
wire transfer of funds, check, or other item of payment Bank may receive to conditionally reduce Obligations, but such applications of funds shall not be considered a payment on account unless such payment is of immediately available federal funds
or unless and until such check or other item of payment is honored when presented for payment. Notwithstanding anything to the contrary contained herein, any wire transfer or payment received by Bank after 5:30 p.m. Eastern time shall be deemed to
have been received by Bank as of the opening of business on the immediately following Business Day. Whenever any payment to Bank under the Loan Documents would otherwise be due (except by reason of acceleration) on a date that is not a Business Day,
such payment shall instead be due on the next Business Day, and additional fees or interest, as the case may be, shall accrue and be payable for the period of such extension. 

2.5 Fees. Borrower shall pay to Bank the following: 

(a) Facility Fee. A fee equal to $20,000, which shall be nonrefundable; 

  
 3. 

 (b) Bank Expenses. On the Closing Date, all Bank Expenses
incurred through the Closing Date , (provided that the legal fees for the first drafts of documents shall not exceed $7,500, and any Bank Expenses incurred through the Closing Date in excess of $15,000 will be shared equally between Bank and
Borrower, provided there are no more than two drafts of Loan Documents), and, after the Closing Date, all Bank Expenses, as and when they become due. 
 2.6 Term. This Agreement shall become effective on the Closing Date and, subject to Section 12.7, shall continue in full force and effect for so long as any Obligations remain
outstanding or Bank has any obligation to make Credit Extensions under this Agreement. Notwithstanding the foregoing, Bank shall have the right to terminate its obligation to make Credit Extensions under this Agreement immediately and without notice
upon the occurrence and during the continuance of an Event of Default. 
 2.7 Lockbox. Borrower
shall, unless otherwise directed by Bank in writing, cause all remittances made by any account debtor for any Accounts to be made to a lock box (the “Lockbox”) maintained with Bank. Unless otherwise directed by Bank in writing, all
invoices and other instructions submitted by Borrower to an account debtor relating to Account payments shall designate the Lockbox as the place to which such payments shall be made. 

 

	 	3.	CONDITIONS OF LOANS. 

 3.1 Conditions Precedent to Initial Credit Extension. The obligation of Bank to make the initial Credit Extension is subject to the condition precedent that Bank shall have received, in form
and substance satisfactory to Bank, the following: 
 (a) this Agreement; 

(b) an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution
and delivery of this Agreement; 
 (c) a financing statement (Form UCC-1); 

(d) payment of the fees and Bank Expenses then due specified in Section 2.5, which may be debited from any of
Borrower’s accounts with Bank; 
 (e) current SOS Reports indicating that except for Permitted Liens,
there are no other security interests or Liens of record in the Collateral; 
 (f) an audit of the
Collateral, the results of which shall be satisfactory to Bank; 
 (g) current financial statements,
including audited statements (or such other level required by the Investment Agreement) for Borrower’s most recently ended fiscal year, together with an unqualified opinion (or an opinion qualified only for going concern so long as
Borrower’s investors provide additional equity as needed), company prepared consolidated and consolidating balance sheets and income statements for the most recently ended month in accordance with Section 6.2, and such other updated
financial information as Bank may reasonably request; 
 (h) current Compliance Certificate in accordance
with Section 6.2; 
 (i) a Warrant in form and substance satisfactory to Bank; and 

(j) such other documents or certificates, and completion of such other matters, as Bank may reasonably request.

 3.2 Conditions Precedent to all Credit Extensions. The obligation of Bank to make each Credit
Extension, including the initial Credit Extension, is further subject to the following conditions: 
 (a)
timely receipt by Bank of the Loan Advance/Paydown Request Form as provided in Section 2.1; and 

  
 4. 

 (b) the representations and warranties contained in Section 4.3
shall be true and correct in all material respects on and as of the date of such Loan Advance/Paydown Request Form and on the effective date of each Credit Extension as though made at and as of each such date, and no Event of Default shall have
occurred and be continuing, or would exist after giving effect to such Credit Extension (provided, however, that those representations and warranties expressly referring to another date shall be true, correct and complete in all material respects as
of such date). The making of each Credit Extension shall be deemed to be a representation and warranty by Borrower on the date of such Credit Extension as to the accuracy of the facts referred to in this Section 3.2. 

 

	 	4.	CREATION OF SECURITY INTEREST. 

 4.1 Grant of Security Interest. Borrower grants and pledges to Bank a continuing security interest in the Collateral to secure prompt repayment of any and all Obligations and to secure
prompt performance by Borrower of each of its covenants and duties under the Loan Documents. Except for Permitted Liens or as disclosed in the Schedule, such security interest constitutes a valid, first priority security interest in the presently
existing Collateral, and will constitute a valid, first priority security interest in later-acquired Collateral. Borrower also hereby agrees not to sell, transfer, assign, mortgage, pledge, lease, grant a security interest in, or encumber any of its
Intellectual Property. Notwithstanding any termination of a financing statement, continuation statement or amendment thereto filed hereunder, Bank’s Lien on the Collateral shall remain in effect for so long as any Obligations are
outstanding. 
 4.2 Perfection of Security Interest. Borrower authorizes Bank to file at any time
financing statements, continuation statements, and amendments thereto that (i) either specifically describe the Collateral or describe the Collateral as all assets of Borrower of the kind pledged hereunder, and (ii) contain any other
information required by the Code for the sufficiency of filing office acceptance of any financing statement, continuation statement, or amendment, including whether Borrower is an organization, the type of organization and any organizational
identification number issued to Borrower, if applicable. Except as disclosed on the Schedule, Borrower shall have possession of the Collateral, except where expressly otherwise provided in this Agreement or where Bank chooses to perfect its security
interest by possession in addition to the filing of a financing statement. Where Collateral is in possession of a third party bailee, Borrower shall take such steps as Bank reasonably requests for Bank to (i) subject to Section 7.10 below,
obtain an acknowledgment, in form and substance satisfactory to Bank, of the bailee that the bailee holds such Collateral for the benefit of Bank, and (ii) obtain “control” of any Collateral consisting of investment property, deposit
accounts, letter-of-credit rights or electronic chattel paper (as such items and the term “control” are defined in Revised Article 9 of the Code) by causing the securities intermediary or depositary institution or issuing bank to execute a
control agreement in form and substance satisfactory to Bank. Borrower will not create any chattel paper without placing a legend on the chattel paper acceptable to Bank indicating that Bank has a security interest in the chattel paper. Borrower
from time to time may deposit with Bank specific cash collateral to secure specific Obligations; Borrower authorizes Bank to hold such specific balances in pledge and to decline to honor any drafts thereon or any request by Borrower or any other
Person to pay or otherwise transfer any part of such balances for so long as the specific Obligations are outstanding. Borrower shall take such other actions as Bank requests to perfect its security interests granted under this Agreement.

  

	 	5.	REPRESENTATIONS AND WARRANTIES. 

 Borrower represents and warrants as follows: 
 5.1 Due
Organization and Qualification. Borrower and each Subsidiary is a corporation duly existing under the laws of the state in which it is organized and qualified and licensed to do business in any state in which the conduct of its business or its
ownership of property requires that it be so qualified, except where the failure to do so would not reasonably be expected to cause a Material Adverse Effect. 

  
 5. 

 5.2 Due Authorization; No Conflict. The execution, delivery,
and performance of the Loan Documents are within Borrower’s powers, have been duly authorized, and are not in conflict with nor constitute a breach of any provision contained in Borrower’s Certificate of Incorporation or Bylaws, nor will
they constitute an event of default under any material agreement by which Borrower is bound. Borrower is not in default under any agreement by which it is bound, except to the extent such default would not reasonably be expected to cause a Material
Adverse Effect. 
 5.3 Collateral. Borrower has rights in or the power to transfer the Collateral,
and its title to the Collateral is free and clear of Liens, adverse claims, and restrictions on transfer or pledge except for Permitted Liens. All Collateral other than movable items of personal property such as laptop computers, having an aggregate
book value not in excess of $100,000 is located solely in the Collateral States. The Eligible Accounts are bona fide existing obligations. The property or services giving rise to such Eligible Accounts has been delivered or rendered to the account
debtor or its agent for immediate shipment to and unconditional acceptance by the account debtor. Borrower has not received notice of actual or imminent Insolvency Proceeding of any account debtor whose accounts are included in any Borrowing Base
Certificate as an Eligible Account. All Inventory is in all material respects of good and merchantable quality, free from all material defects, except for Inventory for which adequate reserves have been made. Except as set forth in the Schedule,
none of the Borrower’s Cash is maintained or invested with a Person other than Bank or Bank’s Affiliates. 
 5.4 Intellectual Property Collateral. Borrower is the sole owner of the intellectual property created or purchased by Borrower, except for licenses granted by Borrower to its customers in
the ordinary course of business. To the best of Borrower’s knowledge, each of the copyrights, trademarks and patents created or purchased by Borrower is valid and enforceable, and no part of the intellectual property created or purchased by
Borrower has been judged invalid or unenforceable, in whole or in part, and no claim has been made to Borrower that any part of the intellectual property created or purchased by Borrower violates the rights of any third party except to the extent
such claim would not reasonably be expected to cause a Material Adverse Effect. Except as set forth in the Schedule, Borrower’s rights as a licensee of intellectual property do not give rise to more than 5% of its gross revenue in any given
month, including without limitation revenue derived from the sale, licensing, rendering or disposition of any product or service. 
 5.5 Name; Location of Chief Executive Office. Except as disclosed in the Schedule, Borrower has not done business under any name other than that specified on the signature page hereof, and
its exact legal name is as set forth in the first paragraph of this Agreement. The chief executive office of Borrower is located at the address indicated in Section 10 hereof. 

5.6 Litigation. Except as set forth in the Schedule, there are no actions or proceedings pending by or
against Borrower or any Subsidiary before any court or administrative agency in which a likely adverse decision would reasonably be expected to have a Material Adverse Effect. 

5.7 No Material Adverse Change in Financial Statements. All consolidated and consolidating financial
statements related to Borrower and any Subsidiary that are delivered by Borrower to Bank fairly present in all material respects Borrower’s consolidated and consolidating financial condition as of the date thereof and Borrower’s
consolidated and consolidating results of operations for the period then ended. There has not been a material adverse change in the consolidated or in the consolidating financial condition of Borrower since the date of the most recent of such
financial statements submitted to Bank. 
 5.8 Solvency, Payment of Debts. Borrower is able to pay
its debts (including trade debts) as they mature; the fair saleable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities; and Borrower is not left with unreasonably small capital
after the transactions contemplated by this Agreement. 
 5.9 Compliance with Laws and Regulations.
Borrower and each Subsidiary have met the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. No event has occurred resulting from Borrower’s failure to comply with ERISA that is reasonably likely
to result in Borrower’s incurring any liability that could have a Material Adverse Effect. Borrower is not an “investment company” or a company “controlled” by an “investment company” within the meaning of the
Investment Company 

  
 6. 

 
Act of 1940. Borrower is not engaged principally, or as one of the important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the
meaning of Regulations T and U of the Board of Governors of the Federal Reserve System). Borrower has not violated any statutes, laws, ordinances or rules applicable to it, the violation of which would reasonably be expected to have a Material
Adverse Effect. Borrower and each Subsidiary have filed or caused to be filed all tax returns required to be filed, and have paid, or have made adequate provision for the payment of, all taxes reflected therein except those being contested in good
faith with adequate reserves under GAAP or where the failure to file such returns or pay such taxes would not reasonably be expected to have a Material Adverse Effect. 

5.10 Subsidiaries. Borrower does not own any stock, partnership interest or other equity securities of any
Person, except for Permitted Investments. 
 5.11 Government Consents. Borrower and each Subsidiary
have obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all governmental authorities that are necessary for the continued operation of Borrower’s business as currently
conducted, except where the failure to do so would not reasonably be expected to cause a Material Adverse Effect. 
 5.12 Inbound Licenses. Except as disclosed on the Schedule, Borrower is not a party to, nor is bound by, any material license or other agreement important for the conduct of Borrower’s
business that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s interest in such license or agreement or any other property important for the conduct of Borrower’s business, other than this Agreement
or the other Loan Documents. 
 5.13 Full Disclosure. No representation, warranty or other
statement made by Borrower in any certificate or written statement furnished to Bank taken together with all such certificates and written statements furnished to Bank contains any untrue statement of a material fact or omits to state a material
fact necessary in order to make the statements contained in such certificates or statements not misleading in light of the circumstances in which they were made, it being recognized by Bank that the projections and forecasts provided by Borrower in
good faith and based upon reasonable assumptions are not to be viewed as facts and that actual results during the period or periods covered by any such projections and forecasts may differ from the projected or forecasted results. 

 

	 	6.	AFFIRMATIVE COVENANTS. 

Borrower covenants that, until payment in full of all outstanding Obligations, and for so long as Bank may have any commitment to make a
Credit Extension hereunder, Borrower shall do all of the following: 
 6.1 Good Standing and
Government Compliance. Borrower shall maintain its and each of its Subsidiaries’ corporate existence and good standing in the respective states of formation, shall maintain qualification and good standing in each other jurisdiction in which
the failure to so qualify would reasonably be expected to have a Material Adverse Effect, and shall furnish to Bank the organizational identification number issued to Borrower by the authorities of the state in which Borrower is organized, if
applicable. Borrower shall meet, and shall cause each Subsidiary to meet, the minimum funding requirements of ERISA with respect to any employee benefit plans subject to ERISA. Borrower shall comply, and shall cause each Subsidiary to comply, with
all statutes, laws, ordinances and government rules and regulations to which it is subject, and shall maintain, and shall cause each of its Subsidiaries to maintain, in force all licenses, approvals and agreements, the loss of which or failure to
comply with which would reasonably be expected to have a Material Adverse Effect. 
 6.2 Financial
Statements, Reports, Certificates. Borrower shall deliver to Bank: (i) as soon as available, but in any event within 30 days after the end of each calendar month, a company prepared consolidated and consolidating balance sheet and income
statement covering Borrower’s operations during such period, in a form reasonably acceptable to Bank and certified by a Responsible Officer; (ii) as soon as available, but in any event within 150 days after the end of Borrower’s
fiscal year, audited (or an opinion qualified for going concern provided that Borrower’s existing investors provide additional equity as needed) consolidated and consolidating financial statements of Borrower prepared in accordance with GAAP,
consistently applied, together with an opinion which is either unqualified, qualified only for going concern so long as Borrower’s investors provide additional equity as needed or otherwise consented to in writing by Bank on such financial
statements of an 

  
 7. 

 
independent certified public accounting firm reasonably acceptable to Bank; (iii) annual financial plan approved by Borrower’s Board of Directors as soon as available but not later than
January 31 for the applicable fiscal year; (iv) if applicable, copies of all statements, reports and notices sent or made available generally by Borrower to its security holders or to any holders of Subordinated Debt and all reports on
Forms 10-K and 10-Q filed with the Securities and Exchange Commission; (v) promptly upon receipt of notice thereof, a report of any legal actions pending or threatened against Borrower or any Subsidiary that could reasonably be expected to
result in damages or costs to Borrower or any Subsidiary of $250,000 or more; (vi) promptly upon receipt, each management letter prepared by Borrower’s independent certified public accounting firm regarding Borrower’s management
control systems; (vii) such budgets, sales projections, operating plans or other financial information as Bank may reasonably request from time to time; (viii) as soon as available, a schedule of Board of Director’s meetings, and
notice of any unscheduled Board of Directors meetings; and (ix) as soon as available, but in any case within five Business Days of presentation to the Board, summaries of all material developments concerning Borrower’s 510k filing and FDA
strategy in the form of written disclosure documents provided to Borrower’s Board of Directors at Board meetings. 
 (a) Within 30 days after the last day of each month, Borrower shall deliver to Bank with the monthly financial statements a Compliance Certificate certified as of the last day of the applicable
month and signed by a Responsible Officer in substantially the form of Exhibit E hereto along with the signed Borrowing Base Certificate in substantially the form of Exhibit D hereto along with agings of accounts receivables and accounts payables.

 (b) As soon as possible and in any event within 3 calendar days after becoming aware of the occurrence
or existence of an Event of Default hereunder, a written statement of a Responsible Officer setting forth details of the Event of Default, and the action which Borrower has taken or proposes to take with respect thereto. 

(c) Bank (through any of its officers, employees, or agents) shall have the right, upon reasonable prior notice and
during Borrower’s usual business hours, from time to time, to inspect Borrower’s Books and to make copies thereof and to check, test, inspect, audit and appraise the Collateral at Borrower’s expense (which shall not exceed $3,000 as
long as an Event of Default has not occurred) in order to verify Borrower’s financial condition or the amount, condition of, or any other matter relating to, the Collateral. 

Borrower may deliver to Bank on an electronic basis any certificates, reports or information required pursuant to this Section 6.2,
and Bank shall be entitled to rely on the information contained in the electronic files, provided that Bank in good faith believes that the files were delivered by a Responsible Officer. Borrower shall include a submission date on any certificates
and reports to be delivered electronically. 
 6.3 Inventory and Equipment; Returns. Borrower shall
keep all Inventory and Equipment in good and merchantable condition, free from all material defects except for Inventory and Equipment (i) sold in the ordinary course of business, and (ii) for which adequate reserves have been made, in all
cases in the United States and such other locations as to which Borrower gives prior written notice. Returns and allowances, if any, as between Borrower and its account debtors shall be on the same basis and in accordance with the usual customary
practices of Borrower, as they exist on the Closing Date. Borrower shall promptly notify Bank of all returns and recoveries and of all disputes and claims involving inventory having a book value of more than $100,000. 

6.4 Taxes. Borrower shall make, and cause each Subsidiary to make, due and timely payment or deposit of all
material federal, state, and local taxes, assessments, or contributions required of it by law, including, but not limited to, those laws concerning income taxes, F.I.C.A., F.U.T.A. and state disability, and will execute and deliver to Bank, on
demand, proof satisfactory to Bank indicating that Borrower or a Subsidiary has made such payments or deposits and any appropriate certificates attesting to the payment or deposit thereof; provided that Borrower or a Subsidiary need not make any
payment if the amount or validity of such payment is contested in good faith by appropriate proceedings and is reserved against (to the extent required by GAAP) by Borrower or such Subsidiary. 

6.5 Insurance. Borrower, at its expense, shall (i) keep the Collateral insured against loss or damage,
and (ii) maintain liability and other insurance, in each case in as ordinarily insured against by other owners in businesses similar to Borrower’s. All such policies of insurance shall be in such form, with such companies, and

  
 8. 

 
in such amounts as reasonably satisfactory to Bank. All policies of property insurance shall contain a lender’s loss payable endorsement, in a form satisfactory to Bank, showing Bank as an
additional loss payee, and all liability insurance policies shall show Bank as an additional insured and specify that the insurer must give at least 20 days notice to Bank before canceling its policy for any reason. Upon Bank’s request,
Borrower shall deliver to Bank certified copies of the policies of insurance and evidence of all premium payments. Proceeds payable under any casualty policy will, at Borrower’s option, be payable to Borrower to replace the property subject to
the claim, provided that any such replacement property shall be deemed Collateral in which Bank has been granted a first priority security interest, provided that if an Event of Default has occurred and is continuing, all proceeds payable under any
such policy shall, at Bank’s option, be payable to Bank to be applied on account of the Obligations. 

6.6 Primary Depository. Within 30 days of the Closing Date, Borrower shall maintain all its depository and
operating accounts with Bank and its primary investment accounts with Bank or Bank’s Affiliates, provided however, that Borrower may maintain a deposit account with the issuing bank securing Borrower’s reimbursement obligations in respect
of the letter of credit listed on the Schedule, the balance in such account not to exceed 105% of the face amount of such letter of credit. 
 6.7 Liquidity. Borrower shall at all times maintain a Liquidity Ratio of at least 1.25 to 1.00, measured monthly. 

6.8 Milestone Covenants. 

(a) Borrower shall have two (2) fully integrated Numera machines at field test sites outside of
Borrower’s headquarters on or before November 30, 2008, confirmed to Bank by Borrower’s Board of Directors, one of such test sites to be the Mayo Clinic or another institution reasonably acceptable to Bank. 

(b) Borrower shall have filed a 510k approval application with the United States Food and Drug Administration for
the Numera machine on or before February 28, 2009, such filing to be confirmed to Bank by Borrower’s Board of Directors. 
 (c) Borrower shall have received 510k clearance from the United States Food and Drug Administration on or before August 31, 2009 to market the Numera machine, such receipt to be confirmed to
Bank by Borrower’s Board of Directors. 
 6.9 Consent of Inbound Licensors. Prior to entering
into or becoming bound by any material inbound license or agreement, Borrower shall: (i) provide written notice to Bank of the material terms of such license or agreement with a description of its likely impact on Borrower’s business or
financial condition; and (ii) in good faith use commercially reasonable efforts to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for Borrower’s interest in such licenses or contract rights to be
deemed Collateral and for Bank to have a security interest in it that might otherwise be restricted by the terms of the applicable license or agreement, whether now existing or entered into in the future, provided, however, that the failure to
obtain any such consent or waiver shall not constitute a default under this Agreement. 
 6.10 Further
Assurances. At any time and from time to time Borrower shall execute and deliver such further instruments and take such further action as may reasonably be requested by Bank to effect the purposes of this Agreement. 

 

	 	7.	NEGATIVE COVENANTS. 

Borrower covenants and agrees that, so long as any credit hereunder shall be available and until the outstanding Obligations are paid in
full or for so long as Bank may have any commitment to make any Credit Extensions, Borrower will not do any of the following without Bank’s prior written consent, which shall not be unreasonably withheld: 

7.1 Dispositions. Convey, sell, lease, license, transfer or otherwise dispose of (collectively, to
“Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, or move cash balances on deposit with Bank to accounts opened at another financial institution, other than Permitted Transfers.

  
 9. 

 7.2 Change in Name, Location, Executive Office, or Executive
Management; Change in Business; Change in Fiscal Year; Change in Control. Change its name or the state of Borrower’s formation or relocate its chief executive office without 30 days prior written notification to Bank; replace its chief
executive officer or chief financial officer without 30 days prior written notification to Bank; engage in any business, or permit any of its Subsidiaries to engage in any business, other than or reasonably related or incidental to the businesses
currently engaged in by Borrower; change its fiscal year end; have a Change in Control. 
 7.3 Mergers
or Acquisitions. Without Bank’s prior written consent, merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into any other business organization (other than mergers or consolidations of a Subsidiary into
another Subsidiary or into Borrower), or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person except where the Obligations are repaid in full concurrently with the closing
of any such merger or consolidation. 
 7.4 Indebtedness. Create, incur, assume, guarantee or be or
remain liable with respect to any Indebtedness, or permit any Subsidiary so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation to prepay any Indebtedness, except
Indebtedness to Bank. 
 7.5 Encumbrances. Create, incur, assume or allow any Lien with respect to
its property, or assign or otherwise convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries so to do, except for Permitted Liens, or covenant to any other Person (other than (i) the licensors
of in-licensed property with respect to such property or (ii) the lessors of specific equipment or lenders financing specific equipment with respect to such leased or financed equipment) that Borrower in the future will refrain from creating,
incurring, assuming or allowing any Lien with respect to any of Borrower’s property. 
 7.6
Distributions. Pay any dividends or make any other distribution or payment on account of or in redemption, retirement or purchase of any capital stock, except that Borrower may (i) repurchase the stock of former employees, consultants or
directors pursuant to stock repurchase agreements as long as an Event of Default does not exist prior to such repurchase or would not exist after giving effect to such repurchase, and (ii) repurchase the stock of former employees, consultants
or directors pursuant to stock repurchase agreements by the cancellation of indebtedness owed by such former employees, consultants or directors to Borrower regardless of whether an Event of Default exists. 

7.7 Investments. Directly or indirectly acquire or own, or make any Investment in or to any Person, or
permit any of its Subsidiaries so to do, other than Permitted Investments, or maintain or invest any of its Investment Property with a Person other than Bank or Bank’s Affiliates or permit any Subsidiary to do so unless such Person has entered
into a control agreement with Bank, in form and substance satisfactory to Bank, or suffer or permit any Subsidiary to be a party to, or be bound by, an agreement that restricts such Subsidiary from paying dividends or otherwise distributing property
to Borrower. 
 7.8 Transactions with Affiliates. Directly or indirectly enter into or permit to
exist any material transaction with any Affiliate of Borrower except for transactions that are in the ordinary course of Borrower’s business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an
arm’s length transaction with a non-affiliated Person. 
 7.9 Subordinated Debt. Make any
payment in respect of any Subordinated Debt, or permit any of its Subsidiaries to make any such payment, except in compliance with the terms of such Subordinated Debt, or amend any provision affecting Bank’s rights contained in any
documentation relating to the Subordinated Debt without Bank’s prior written consent. 

  
 10.

 7.10 Inventory and Equipment. Store the Inventory or the
Equipment of a book value in excess of $100,000 with a bailee, warehouseman, or similar third party unless the third party has been notified of Bank’s security interest and Bank (a) has received an acknowledgment from the third party that
it is holding or will hold the Inventory or Equipment for Bank’s benefit or (b) is in possession of the warehouse receipt, where negotiable, covering such Inventory or Equipment. Except for Inventory sold in the ordinary course of business
and except for such other locations as set forth on the Schedule or which Bank may approve in writing, Borrower shall keep the Inventory and Equipment only at the location set forth in Section 10 and such other locations of which Borrower gives
Bank prior written notice and as to which Bank is able to take such actions as may be necessary needed to perfect its security interest or to obtain a bailee’s acknowledgment of Bank’s rights in the Collateral. 

7.11 Batelle Agreement. Make any payments on account of the letter agreement between Battelle Memorial
Institute and Borrower dated May 2, 2007 other than regularly scheduled payments of up to $150,000 per month after the commercial launch of the Numera device, provided that an Event of Default is not then continuing or an Event of Default would
not exist after giving effect to such payments. Borrower shall not begin payments to Batelle until Borrower’s Board of Directors have confirmed with Bank that the Numera device has been commercially launched and that payments to Batelle shall
not materially impair Borrower’s ability to operate. 
 7.12 No Investment Company; Margin
Regulation. Become or be controlled by an “investment company,” within the meaning of the Investment Company Act of 1940, or become principally engaged in, or undertake as one of its important activities, the business of extending
credit for the purpose of purchasing or carrying margin stock, or use the proceeds of any Credit Extension for such purpose. 
  

	 	8.	EVENTS OF DEFAULT. 

 Any
one or more of the following events shall constitute an Event of Default by Borrower under this Agreement: 

8.1 Payment Default. If Borrower fails to pay any of the Obligations when due; 

8.2 Covenant Default. 

(a) If Borrower fails to perform any obligation under Article 6 or violates any of the covenants contained in
Article 7 of this Agreement; or 
 (b) If Borrower fails or neglects to perform or observe any other
material term, provision, condition, covenant contained in this Agreement, in any of the Loan Documents, or in any other present or future agreement between Borrower and Bank and as to any default under such other term, provision, condition or
covenant that can be cured, has failed to cure such default within 10 days after Borrower receives notice thereof or any officer of Borrower becomes aware thereof; provided, however, that if the default cannot by its nature be cured within the 10
day period or cannot after diligent attempts by Borrower be cured within such 10 day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional reasonable period (which shall not in any case
exceed 30 days) to attempt to cure such default, and within such reasonable time period the failure to have cured such default shall not be deemed an Event of Default but no Credit Extensions will be made; 

8.3 Material Adverse Change. If there occurs any circumstance or any circumstances which would reasonably be
expected to have a Material Adverse Effect; 
 8.4 Attachment. If any material portion of
Borrower’s assets is attached, seized, subjected to a writ or distress warrant, or is levied upon, or comes into the possession of any trustee, receiver or person acting in a similar capacity and such attachment, seizure, writ or distress
warrant or levy has not been removed, discharged or rescinded within 10 days, or if Borrower is enjoined, restrained, or in any way prevented by court order from continuing to conduct all or any material part of its business affairs, or if a
judgment or other claim becomes a lien or encumbrance upon any material portion of Borrower’s assets, or if a notice of lien, levy, or assessment is filed of record with respect to any material portion of Borrower’s assets by the United
States Government, or any 

  
 11.

 
department, agency, or instrumentality thereof, or by any state, county, municipal, or governmental agency, and the same is not paid within ten days after Borrower receives notice thereof,
provided that none of the foregoing shall constitute an Event of Default where such action or event is stayed or an adequate bond has been posted pending a good faith contest by Borrower (provided that no Credit Extensions will be made during such
cure period); 
 8.5 Insolvency. If Borrower becomes insolvent, or if an Insolvency Proceeding is
commenced by Borrower, or if an Insolvency Proceeding is commenced against Borrower and is not dismissed or stayed within 30 days (provided that no Credit Extensions will be made prior to the dismissal of such Insolvency Proceeding); 

8.6 Other Agreements. If there is a default or other failure to perform in any agreement to which Borrower
is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of $250,000 or that would reasonably be expected to have a
Material Adverse Effect; 
 8.7 Judgments. If a judgment or judgments for the payment of money in
an amount, individually or in the aggregate, of at least $250,000 shall be rendered against Borrower and shall remain unsatisfied and unstayed for a period of 10 days (provided that no Credit Extensions will be made prior to the satisfaction or stay
of the judgment); or 
 8.8 Misrepresentations. If any material misrepresentation or material
misstatement exists now or hereafter in any warranty or representation set forth herein or in any certificate delivered to Bank by any Responsible Officer pursuant to this Agreement or to induce Bank to enter into this Agreement or any other Loan
Document. 
  

	 	9.	BANK’S RIGHTS AND REMEDIES. 

 9.1 Rights and Remedies. Upon the occurrence and during the continuance of an Event of Default, Bank may, at its election, without notice of its election and without demand, do any one or
more of the following, all of which are authorized by Borrower: 
 (a) Declare all Obligations, whether
evidenced by this Agreement, by any of the other Loan Documents, or otherwise, immediately due and payable (provided that upon the occurrence of an Event of Default described in Section 8.5 (insolvency), all Obligations shall become immediately
due and payable without any action by Bank); 
 (b) Demand that Borrower (i) deposit cash with Bank
in an amount equal to the amount of any Letters of Credit remaining undrawn, as collateral security for the repayment of any future drawings under such Letters of Credit, and (ii) pay in advance all Letter of Credit fees scheduled to be paid or
payable over the remaining term of the Letters of Credit, and Borrower shall promptly deposit and pay such amounts; 
 (c) Cease advancing money or extending credit to or for the benefit of Borrower under this Agreement or under any other agreement between Borrower and Bank; 

(d) Settle or adjust disputes and claims directly with account debtors for amounts, upon terms and in whatever
order that Bank reasonably considers advisable; 
 (e) Make such payments and do such acts as Bank
considers necessary or reasonable to protect its security interest in the Collateral. Borrower agrees to assemble the Collateral if Bank so requires, and to make the Collateral available to Bank as Bank may designate. Borrower authorizes Bank to
enter the premises where the Collateral is located, to take and maintain possession of the Collateral, or any part of it, and to pay, purchase, contest, or compromise any encumbrance, charge, or lien which in Bank’s determination appears to be
prior or superior to its security interest and to pay all expenses incurred in connection therewith. With respect to any of Borrower’s owned premises, Borrower hereby grants Bank a license to enter into possession of such premises and to occupy
the same, without charge, in order to exercise any of Bank’s rights or remedies provided herein, at law, in equity, or otherwise; 

  
 12.

 (f) Set off and apply to the Obligations any and all
(i) balances and deposits of Borrower held by Bank, and (ii) indebtedness at any time owing to or for the credit or the account of Borrower held by Bank; 

(g) Ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell (in the
manner provided for herein) the Collateral. Bank is hereby granted a license or other right, solely pursuant to the provisions of this Section 9.1, to use, without charge, Borrower’s labels, patents, copyrights, rights of use of any name,
trade secrets, trade names, trademarks, service marks, and advertising matter, or any property of a similar nature, as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, solely for the
purpose of and in connection with Bank’s exercise of its rights under this Section 9.1, Borrower’s rights under all licenses and all franchise agreements shall inure to Bank’s benefit; 

(h) Sell the Collateral at either a public or private sale, or both, by way of one or more contracts or
transactions, for cash or on terms, in such manner and at such places (including Borrower’s premises) as Bank determines is commercially reasonable, and apply any proceeds to the Obligations in whatever manner or order Bank deems appropriate.
Bank may sell the Collateral without giving any warranties as to the Collateral. Bank may specifically disclaim any warranties of title or the like. This procedure will not be considered adversely to affect the commercial reasonableness of any sale
of the Collateral. If Bank sells any of the Collateral upon credit, Borrower will be credited only with payments actually made by the purchaser, received by Bank, and applied to the indebtedness of the purchaser. If the purchaser fails to pay for
the Collateral, Bank may resell the Collateral and Borrower shall be credited with the proceeds of the sale; 

(i) Bank may credit bid and purchase at any public sale; 

(j) Apply for the appointment of a receiver, trustee, liquidator or conservator of the Collateral, without notice
and without regard to the adequacy of the security for the Obligations and without regard to the solvency of Borrower, any guarantor or any other Person liable for any of the Obligations; and 

(k) Any deficiency that exists after disposition of the Collateral as provided above will be paid immediately by
Borrower. 
 Bank may comply with any applicable state or federal law requirements in connection with a disposition of the Collateral and
compliance will not be considered adversely to affect the commercial reasonableness of any sale of the Collateral. 
 9.2 Power of Attorney. Effective only upon the occurrence and during the continuance of an Event of Default, Borrower hereby irrevocably appoints Bank (and any of Bank’s designated
officers, or employees) as Borrower’s true and lawful attorney to: (a) send requests for verification of Accounts or notify account debtors of Bank’s security interest in the Accounts; (b) endorse Borrower’s name on any
checks or other forms of payment or security that may come into Bank’s possession; (c) sign Borrower’s name on any invoice or bill of lading relating to any Account, drafts against account debtors, schedules and assignments of
Accounts, verifications of Accounts, and notices to account debtors; (d) dispose of any Collateral; (e) make, settle, and adjust all claims under and decisions with respect to Borrower’s policies of insurance; (f) settle and
adjust disputes and claims respecting the accounts directly with account debtors, for amounts and upon terms which Bank determines to be reasonable; and (g) file, in its sole discretion, one or more financing or continuation statements and
amendments thereto, relative to any of the Collateral without the signature of Borrower where permitted by law; provided Bank may exercise such power of attorney to sign the name of Borrower on any of the documents described in clause
(g) above, regardless of whether an Event of Default has occurred. The appointment of Bank as Borrower’s attorney in fact, and each and every one of Bank’s rights and powers, being coupled with an interest, is irrevocable until all of
the Obligations have been fully repaid and performed and Bank’s obligation to provide advances hereunder is terminated. 

  
 13.

 9.3 Accounts Collection. At any time after the occurrence and
during the continuation of an Event of Default, Bank may notify any Person owing funds to Borrower of Bank’s security interest in such funds and verify the amount of such Account. Borrower shall collect all amounts owing to Borrower for Bank,
receive in trust all payments as Bank’s trustee, and immediately deliver such payments to Bank in their original form as received from the account debtor, with proper endorsements for deposit. 

9.4 Bank Expenses. If Borrower fails to pay any amounts or furnish any required proof of payment due to
third persons or entities, as required under the terms of this Agreement, then Bank may do any or all of the following after reasonable notice to Borrower: (a) make payment of the same or any part thereof; (b) set up such reserves under
the Revolving Line as Bank deems necessary to protect Bank from the exposure created by such failure; or (c) obtain and maintain insurance policies of the type discussed in Section 6.5 of this Agreement, and take any action with respect to
such policies as Bank deems prudent. Any amounts so paid or deposited by Bank shall constitute Bank Expenses, shall be immediately due and payable, and shall bear interest at the then applicable rate hereinabove provided, and shall be secured by the
Collateral. Any payments made by Bank shall not constitute an agreement by Bank to make similar payments in the future or a waiver by Bank of any Event of Default under this Agreement. 

9.5 Bank’s Liability for Collateral. Bank has no obligation to clean up or otherwise prepare the
Collateral for sale. All risk of loss, damage or destruction of the Collateral shall be borne by Borrower. 

9.6 No Obligation to Pursue Others. Bank has no obligation to attempt to satisfy the Obligations by
collecting them from any other person liable for them and Bank may release, modify or waive any collateral provided by any other Person to secure any of the Obligations, all without affecting Bank’s rights against Borrower. Borrower waives any
right it may have to require Bank to pursue any other Person for any of the Obligations. 
 9.7
Remedies Cumulative. Bank’s rights and remedies under this Agreement, the Loan Documents, and all other agreements shall be cumulative. Bank shall have all other rights and remedies not inconsistent herewith as provided under the Code,
by law, or in equity. No exercise by Bank of one right or remedy shall be deemed an election, and no waiver by Bank of any Event of Default on Borrower’s part shall be deemed a continuing waiver. No delay by Bank shall constitute a waiver,
election, or acquiescence by it. No waiver by Bank shall be effective unless made in a written document signed on behalf of Bank and then shall be effective only in the specific instance and for the specific purpose for which it was given. Borrower
expressly agrees that this Section 9.7 may not be waived or modified by Bank by course of performance, conduct, estoppel or otherwise. 
 9.8 Demand; Protest. Except as otherwise provided in this Agreement, Borrower waives demand, protest, notice of protest, notice of default or dishonor, notice of payment and nonpayment and
any other notices relating to the Obligations. 
  

	 	10.	NOTICES. 

 Unless
otherwise provided in this Agreement, all notices or demands by any party relating to this Agreement or any other agreement entered into in connection herewith shall be in writing and (except for financial statements and other informational
documents which may be sent by first-class mail, postage prepaid) shall be personally delivered or sent by a recognized overnight delivery service, certified mail, postage prepaid, return receipt requested, or by telefacsimile to Borrower or to
Bank, as the case may be, at its addresses set forth below: 
  

			
	If to Borrower:	 	 LIPOSCIENCE, INC.
 2500
Sumner Blvd.
 Raleigh, NC 27616
 Attn:
Chief Financial Officer
 FAX: (919) 872-5927

  
 14.

			
	With a Copy to:	 	 Hutchison Law Group PLLC

5410 Trinity Road, Suite 400
 Raleigh, North
Carolina 27607
 Attn: Holly A. Coldiron, Esq.
 FAX: (919) 829-9696

		
	If to Bank:	 	 Square 1 Bank
 406 Blackwell
Street, Suite 240
 Durham, North Carolina 27701
 Attn: Loan Operations Manager
 and Jeff Welch

FAX: (919) 314-3080

 Any notice or demand delivered to a party in accordance with this Section shall be valid despite the failure to provide a copy to any Person not party to this Agreement. The parties hereto may change the
address at which they are to receive notices hereunder, by notice in writing in the foregoing manner given to the other. 
  

	 	11.	CHOICE OF LAW AND VENUE; JURY TRIAL WAIVER. 

 This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of North Carolina, without regard to principles of conflicts of law. Jurisdiction shall lie in the
State of North Carolina. BANK AND BORROWER EACH ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED. EACH OF THEM, AFTER CONSULTING OR HAVING HAD THE OPPORTUNITY TO CONSULT, WITH COUNSEL OF THEIR CHOICE,
KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT ANY OF THEM MAY HAVE TO A TRIAL BY JURY IN ANY LITIGATION BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY RELATED INSTRUMENT OR LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED BY
THIS AGREEMENT OR ANY COURSE OF CONDUCT, DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTION OF ANY OF THEM. THESE PROVISIONS SHALL NOT BE DEEMED TO HAVE BEEN MODIFIED IN ANY RESPECT OR RELINQUISHED BY BANK OR BORROWER, EXCEPT BY A WRITTEN
INSTRUMENT EXECUTED BY EACH OF THEM. If the jury waiver set forth in this Section 11 is not enforceable, then any dispute, controversy or claim arising out of or relating to this Agreement, the Loan Documents or any of the transactions
contemplated therein shall be settled by final and binding arbitration held in Durham County, North Carolina in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association by one arbitrator appointed in
accordance with those rules. The arbitrator shall apply North Carolina law to the resolution of any dispute, without reference to rules of conflicts of law or rules of statutory arbitration. Judgment upon any award resulting from arbitration may be
entered into and enforced by any state or federal court having jurisdiction thereof. Notwithstanding the foregoing, the parties may apply to any court of competent jurisdiction for preliminary or interim equitable relief, or to compel arbitration in
accordance with this Section. The expenses of the arbitration, including the arbitrator’s fees and expert witness fees, incurred by the parties to the arbitration may be awarded to the prevailing party, in the discretion of the arbitrator, or
may be apportioned between the parties in any manner deemed appropriate by the arbitrator. Unless and until the arbitrator decides that one party is to pay for all (or a share) of such expenses, both parties shall share equally in the payment of the
arbitrator’s fees as and when billed by the arbitrator. 
  

	 	12.	GENERAL PROVISIONS. 

 12.1 Successors and Assigns. This Agreement shall bind and inure to the benefit of the respective successors and permitted assigns of each of the parties and shall bind all persons who
become bound as a debtor to this Agreement; provided, however, that neither this Agreement nor any rights hereunder may be assigned by Borrower without Bank’s prior written consent, which consent may be granted or withheld in Bank’s sole
discretion. Bank shall have the right without the consent of or notice to Borrower to sell, transfer, negotiate, or grant participation in all or any part of, or any interest in, Bank’s obligations, rights and benefits hereunder. 

  
 15.

 12.2 Indemnification. Borrower shall defend, indemnify and
hold harmless Bank and its officers, employees, and agents against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Agreement; and
(b) all losses or Bank Expenses in any way suffered, incurred, or paid by Bank, its officers, employees and agents as a result of or in any way arising out of, following, or consequential to transactions between Bank and Borrower whether under
this Agreement, or otherwise (including without limitation reasonable attorneys fees and expenses), except for losses caused by Bank’s gross negligence or willful misconduct. 

12.3 Time of Essence. Time is of the essence for the performance of all obligations set forth in this
Agreement. 
 12.4 Severability of Provisions. Each provision of this Agreement shall be severable
from every other provision of this Agreement for the purpose of determining the legal enforceability of any specific provision. 
 12.5 Amendments in Writing, Integration. All amendments to or terminations of this Agreement or the other Loan Documents must be in writing. All prior agreements, understandings,
representations, warranties, and negotiations between the parties hereto with respect to the subject matter of this Agreement and the other Loan Documents, if any, are merged into this Agreement and the Loan Documents. 

12.6 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on
separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Agreement. 

12.7 Survival. All covenants, representations and warranties made in this Agreement shall continue in full
force and effect so long as any Obligations remain outstanding or Bank has any obligation to make any Credit Extension to Borrower. The obligations of Borrower to indemnify Bank with respect to the expenses, damages, losses, costs and liabilities
described in Section 12.2 shall survive until all applicable statute of limitations periods with respect to actions that may be brought against Bank have run. 

12.8 Confidentiality. In handling any confidential information, Bank and all employees and agents of Bank
shall exercise the same degree of care that Bank exercises with respect to its own proprietary information of the same types (but in no event less than reasonable care) to maintain the confidentiality of any non-public information thereby received
or received pursuant to this Agreement except that disclosure of such information may be made (i) to the subsidiaries or Affiliates of Bank in connection with their present or prospective business relations with Borrower, (ii) to
prospective transferees or purchasers of any interest in the Credit Extensions, provided that they have entered into a comparable confidentiality agreement in favor of Borrower and have delivered a copy to Borrower, (iii) as required by law,
regulations, rule or order, subpoena, judicial order or similar order, (iv) as may be required in connection with the examination, audit or similar investigation of Bank and (v) as Bank may determine in connection with the enforcement of
any remedies hereunder. Confidential information hereunder shall not include information that either: (a) is in the public domain or in the knowledge or possession of Bank when disclosed to Bank, or becomes part of the public domain after
disclosure to Bank through no fault of Bank; or (b) is disclosed to Bank by a third party, provided Bank does not have actual knowledge that such third party is prohibited from disclosing such information. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. 
 SIGNATURE PAGE FOLLOWS.] 

  
 16.

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first above
written. 
  

			
	LIPOSCIENCE, INC.
		
	By:	 	/s/ Lucy G. Martindale
		
	Title:	 	Chief Financial Officer

  

			
	SQUARE 1 BANK
		
	By:	 	/s/ Illegible
		
	Title:	 	Asst VP

  
 1. 

 EXHIBIT A 
 DEFINITIONS 
 “Accounts” means all presently existing and hereafter arising accounts,
contract rights, payment intangibles and all other forms of obligations owing to Borrower arising out of the sale or lease of goods (including, without limitation, the licensing of software and other technology) or the rendering of services by
Borrower and any and all credit insurance, guaranties, and other security therefor, as well as all merchandise returned to or reclaimed by Borrower and Borrower’s Books relating to any of the foregoing. 

“Advance” or “Advances” means a cash advance or cash advances under the Revolving Line. 

“Affiliate” means, with respect to any Person, any Person that owns or controls directly or indirectly such Person, any Person that controls or
is controlled by or is under common control with such Person, and each of such Person’s senior executive officers, directors, and general partners. 
 “Ancillary Services” means any of the following products or services requested by Borrower and approved by Bank under the Revolving Line, including, without limitation, Automated Clearing House
transactions, corporate credit cards, FX Contracts, Letters of Credit, or other treasury management services. 
 “Ancillary Services
Sublimit” means a sublimit for Ancillary Services under the Revolving Line not to exceed $300,000 for general Ancillary Services (including up to $30,000 for credit cards), plus $350,000 for a Letter of Credit to support Borrower’s credit
cards, plus $750,000 for Letters of Credit to support inventory purchases by Borrower’s contract manufacturers. 
 “Bank
Expenses” means all reasonable costs or expenses (including reasonable attorneys’ fees and expenses) incurred in connection with the preparation, negotiation, administration, and enforcement of the Loan Documents; reasonable Collateral
audit fees; and Bank’s reasonable attorneys’ fees and expenses (whether generated in-house or by outside counsel) incurred in amending, enforcing or defending the Loan Documents (including fees and expenses of appeal), incurred before,
during and after an Insolvency Proceeding, whether or not suit is brought. 
 “Borrower’s Books” means all of Borrower’s
books and records including: ledgers; records concerning Borrower’s assets or liabilities, the Collateral, business operations or financial condition; and all computer programs, or tape files, and the equipment, containing such information.

 “Borrowing Base” means an amount equal to 80% of Eligible Accounts, as determined by Bank with reference to the most recent
Borrowing Base Certificate delivered by Borrower. 
 “Business Day” means any day that is not a Saturday, Sunday, or other day on
which banks in the State of North Carolina are authorized or required to close. 
 “Cash” means unrestricted cash and cash
equivalents. 
 “Change in Control” shall mean a transaction in which any “person” or “group” (within the meaning
of Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934) becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of a sufficient number of shares of all
classes of stock then outstanding of Borrower ordinarily entitled to vote in the election of directors, empowering such “person” or “group” to elect a majority of the Board of Directors of Borrower, who did not have such power
before such transaction. 
 “Closing Date” means the date of this Agreement. 
 “Code” means the North Carolina Uniform Commercial Code as amended or supplemented from time to time. 

  
 1. 

 “Collateral” means the property described on Exhibit B attached hereto and all Negotiable
Collateral to the extent not described on Exhibit B, except to the extent any such property (i) is nonassignable by its terms without the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is
enforceable under applicable law, including, without limitation, Sections 9406 and 9408 of the Code), (ii) the granting of a security interest therein is contrary to applicable law, provided that upon the cessation of any such restriction or
prohibition, such property shall automatically become part of the Collateral, (iii) constitutes the capital stock of a controlled foreign corporation (as defined in the IRC), in excess of 65% of the voting power of all classes of capital stock
of such controlled foreign corporations entitled to vote, or (iv) property (including any attachments, accessions or replacements) that is subject to a Lien that is permitted pursuant to clause (c) of the definition of Permitted Liens, if
the grant of a security interest with respect to such property pursuant to this Agreement would be prohibited by the agreement creating such Permitted Lien or would otherwise constitute a default thereunder, provided, that such property will be
deemed “Collateral” hereunder upon the termination and release of such Permitted Lien. 
 “Collateral State” means the state
or states where the Collateral is located, which are North Carolina, Minnesota and New Hampshire. 
 “Contingent
Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including,
without limitation, any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which that Person is otherwise directly or indirectly liable; (ii) any obligations
with respect to undrawn letters of credit, corporate credit cards or merchant services issued for the account of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate cap
agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent
Obligation” shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determined amount of the primary obligation
in respect of which such Contingent Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by such Person in good faith; provided, however, that such amount shall not in
any event exceed the maximum amount of the obligations under the guarantee or other support arrangement. 
 “Copyrights” means any and
all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or
hereafter existing, created, acquired or held. 
 “Credit Extension” means each Advance, Term Advance, Ancillary Service, or any other
extension of credit by Bank to or for the benefit of Borrower hereunder. 
 “Eligible Accounts” means those Accounts that arise in the
ordinary course of Borrower’s business that comply with all of Borrower’s representations and warranties to Bank set forth in Section 5.3; provided, that Bank may change the standards of eligibility by giving Borrower 30 days prior
written notice. Unless otherwise agreed to by Bank, Eligible Accounts shall not include the following: 
 (a) Account credit balances
greater than 90 days from invoice date; 
 (b) Accounts with respect to an account debtor, 25% of whose Accounts the account debtor has
failed to pay within 120 days of invoice date; 
 (c) Accounts with respect to an account debtor, including Subsidiaries and Affiliates,
whose total obligations to Borrower exceed 25% of all Accounts, to the extent such obligations exceed the aforementioned percentage, except as approved in writing by Bank; 
 (d) Accounts with respect to which the account debtor does not have its principal place of business in the United States, except for Eligible Foreign Accounts; 

  
 2. 

 (e) Accounts with respect to which the account debtor is the United States or any department, agency,
or instrumentality of the United States (other than Medicare and Medicaid accounts which do not fall under clauses (k) and (l) below); 
 (f) Accounts with respect to which Borrower is liable to the account debtor for goods sold or services rendered by the account debtor to Borrower, but only to the extent of any amounts owing to the
account debtor against amounts owed to Borrower; 
 (g) Accounts with respect to which the account debtor is an officer, employee, agent
or Affiliate of Borrower; 
 (h) Accounts with respect to which goods are placed on consignment, guaranteed sale, sale or return, sale on
approval, bill and hold, demo or promotional, or other terms by reason of which the payment by the account debtor may be conditional; 

(i) “Advanced Billings,” i.e., accounts that have not yet been billed to the account debtor or that relate to deposits (such as good
faith deposits) or other property of the account debtor held by Borrower for the performance of services or delivery of goods which Borrower has not yet performed or delivered; 
 (j) Accounts with respect to which the account debtor disputes liability or makes any claim with respect thereto as to which Bank believes, in its sole discretion, that there may be a basis for
dispute (but only to the extent of the amount subject to such dispute or claim), or is subject to any Insolvency Proceeding, or becomes insolvent, or goes out of business; 
 (k) Medicare account balances aged greater than 60 days after test completion date; 

(l) Medicaid account balances greater than 90 days after test completion date; 
 (m) Account balances other than Medicare or Medicaid that are more than 120 days after test completion date; 
 (n) Accounts arising from personal injury claims; 
 (o) Accounts the collection of
which Bank reasonably determines after inquiry and consultation with Borrower to be doubtful; 
 (p) Retentions and hold-backs (including
contractual allowances and bad debt reserves); and 
 (q) “Project Billings,” i.e., accounts that are billed based on project
milestones and not on actual time and materials bases. 
 “Eligible Foreign Accounts” means Accounts with respect to which the account
debtor does not have its principal place of business in the United States and that are (i) supported by one or more letters of credit in an amount and of a tenor, and issued by a financial institution, acceptable to Bank, (ii) insured by
the Export Import Bank of the United States, (iii) generated by an account debtor with its principal place of business in Canada, provided that the Bank has perfected its security interest in the appropriate Canadian province, or
(iv) approved by Bank on a case-by-case basis. All Eligible Foreign Accounts must be calculated in U.S. Dollars. 
 “Environmental
Laws” means all laws, rules, regulations, orders and the like issued by any federal state, local foreign or other governmental or quasi-governmental authority or any agency pertaining to the environment or to any hazardous materials or wastes,
toxic substances, flammable, explosive or radioactive materials, asbestos or other similar materials. 
 “Equipment” means all present
and future machinery, equipment, tenant improvements, furniture, fixtures, vehicles, tools, parts and attachments in which Borrower has any interest. 

  
 3. 

 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended, and the regulations
thereunder. 
 “Event of Default” has the meaning assigned in Article 8. 
 “FX Amount” means the amount determined by multiplying (i) the aggregate amount, in United States Dollars, of FX Contracts between Borrower and Bank remaining outstanding as of any date of
determination by (ii) the applicable Foreign Exchange Reserve Percentage as of such date. 
 “FX Contracts” means contracts
between Borrower and Bank for foreign exchange transactions. 
 “Foreign Exchange Reserve Percentage” means a percentage of reserves
for FX Contracts as determined by Bank, in its sole discretion from time to time. The initial Foreign Exchange Reserve Percentage shall be ten percent (10%). 
 “GAAP” means generally accepted accounting principles, consistently applied, as in effect from time to time. 
 “Indebtedness” means (a) all indebtedness for borrowed money or the deferred purchase price of property or services, including without limitation reimbursement and other obligations with
respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations, including but not limited to any
sublimit contained herein. 
 “Insolvency Proceeding” means any proceeding commenced by or against any Person or entity under any
provision of the United States Bankruptcy Code, as amended, or under any other bankruptcy or insolvency law, including assignments for the benefit of creditors, formal or informal moratoria, compositions, extension generally with its creditors, or
proceedings seeking reorganization, arrangement, or other relief. 
 “Intellectual Property Collateral” means all of Borrower’s
right, title, and interest in and to the following: 
 (a) Copyrights, Trademarks and Patents; 

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter
existing, created, acquired or held; 
 (c) Any and all design rights which may be available to Borrower now or hereafter existing,
created, acquired or held; 
 (d) Any and all claims for damages by way of past, present and future infringement of any of the rights
included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above; 
 (e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights; and

 (f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents. 

“Inventory” means all present and future inventory in which Borrower has any interest. 

“Investment” means any beneficial ownership of (including stock, partnership or limited liability company interest or other securities) any
Person, or any loan, advance or capital contribution to any Person. 
 “Investment Agreement” means, collectively, Borrower’s
stock purchase and other agreement(s) pursuant to which Borrower most recently issued its preferred stock. 
 “IRC” means the Internal
Revenue Code of 1986, as amended, and the regulations thereunder. 

  
 4. 

 “Letter of Credit” means a commercial or standby letter of credit or similar undertaking issued by
Bank at Borrower’s request in accordance with Section 2.1(b)(iii). 
 “Lien” means any mortgage, lien, deed of trust,
charge, pledge, security interest or other encumbrance. 
 “Liquidity” means the sum of Cash in Bank or subject to control agreements
acceptable to Bank plus 80% of Eligible Accounts. 
 “Liquidity Ratio” means the ratio of Liquidity to all Indebtedness to Bank.

 “Loan Documents” means, collectively, this Agreement, any note or notes executed by Borrower, and any other document, instrument or
agreement entered into in connection with this Agreement, all as amended or extended from time to time. 
 “Material Adverse Effect”
means a material adverse effect on (i) the operations, business or financial condition of Borrower and its Subsidiaries taken as a whole, (ii) the ability of Borrower to repay the Obligations or otherwise perform its obligations under the
Loan Documents, (iii) Borrower’s interest in, or the value, perfection or priority of Bank’s security interest in the Collateral. 
 “Negotiable Collateral” means all of Borrower’s present and future letters of credit of which it is a beneficiary, drafts, instruments (including promissory notes), securities, documents of
title, and chattel paper, and Borrower’s Books relating to any of the foregoing. 
 “Obligations” means all debt, principal,
interest, Bank Expenses and other amounts owed to Bank by Borrower pursuant to this Agreement or any other agreement, whether absolute or contingent, due or to become due, now existing or hereafter arising, including any interest that accrues after
the commencement of an Insolvency Proceeding and including any debt, liability, or obligation owing from Borrower to others that Bank may have obtained by assignment or otherwise. 
 “Patents” means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and
continuations-in-part of the same. 
 “Periodic Payments” means all installments or similar recurring payments that Borrower may now
or hereafter become obligated to pay to Bank pursuant to the terms and provisions of any instrument, or agreement now or hereafter in existence between Borrower and Bank. 
 “Permitted Indebtedness” means: 
 (a) Indebtedness of Borrower in favor of Bank
arising under this Agreement or any other Loan Document; 
 (b) Indebtedness existing on the Closing Date and disclosed in the Schedule;

 (c) Indebtedness not to exceed $250,000 in the aggregate in any fiscal year of Borrower secured by a lien described in clause
(c) of the defined term “Permitted Liens,” provided such Indebtedness does not exceed at the time it is incurred the lesser of the cost or fair market value of the property financed with such Indebtedness; 

(d) Subordinated Debt; 
 (e)
Indebtedness to trade creditors incurred in the ordinary course of business; and 
 (f) Extensions, refinancings and renewals of any
items of Permitted Indebtedness, provided that the principal amount is not increased or the terms modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be. 
 “Permitted Investment” means: 
 (a) Investments existing on the Closing Date
disclosed in the Schedule; 

  
 5. 

 (b) (i) Marketable direct obligations issued or unconditionally guaranteed by the United States of
America or any agency or any State thereof maturing within one year from the date of acquisition thereof, (ii) commercial paper maturing no more than one year from the date of creation thereof and currently having rating of at least A-2 or P-2
from either Standard & Poor’s Corporation or Moody’s Investors Service, (iii) Bank’s certificates of deposit maturing no more than one year from the date of investment therein, and (iv) Bank’s money market
accounts; (v) Investments in regular deposit or checking accounts held with Bank or subject to a control agreement in favor of Bank; and (vi) Investments consistent with any investment policy adopted by the Borrower’s board of
directors; 
 (c) Repurchases of stock from former employees or directors of Borrower under the terms of applicable repurchase agreements
(i) in an aggregate amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing or would exist after giving effect to the repurchases, or (ii) in any amount where the consideration for
the repurchase is the cancellation of indebtedness owed by such former employees to Borrower regardless of whether an Event of Default exists; 

(d) Investments accepted in connection with Permitted Transfers; 
 (e) Investments of Subsidiaries in or to other Subsidiaries or Borrower and Investments by Borrower in Subsidiaries not to exceed $250,000 in the aggregate in any fiscal year; 

(f) Investments not to exceed $250,000 outstanding in the aggregate at any time consisting of (i) travel advances and employee relocation
loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase
plan agreements approved by Borrower’s Board of Directors; 
 (g) Investments in unfinanced capital expenditures in any fiscal year,
not to exceed $250,000; 
 (h) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of
customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s business; 
 (i) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business, provided
that this subparagraph (h) shall not apply to Investments of Borrower in any Subsidiary; 
 (j) Joint ventures or strategic
alliances in the ordinary course of Borrower’s business consisting of the non-exclusive licensing of technology, the development of technology or the providing of technical support, provided that any cash Investments by Borrower do not exceed
$250,000 in the aggregate in any fiscal year; and 
 (k) Investments permitted under Section 7.3. 

“Permitted Liens” means the following: 
 (a) Any Liens existing on the Closing Date and disclosed in the Schedule (excluding Liens to be satisfied with the proceeds of the Credit Extensions) or arising under this Agreement, the other Loan
Documents, or any other agreement in favor of Bank; 
 (b) Liens for taxes, fees, assessments or other governmental charges or levies,
either not delinquent or being contested in good faith by appropriate proceedings and for which Borrower maintains adequate reserves; 
 (c)
Liens not to exceed $250,000 in the aggregate (i) upon or in any Equipment (other than Equipment financed by a Credit Extension) acquired or held by Borrower or any of its Subsidiaries to secure the purchase price of such Equipment or
indebtedness incurred solely for the purpose of financing the acquisition or lease of such Equipment, or (ii) existing on such Equipment at the time of its acquisition, provided that the Lien is confined solely to the property so acquired and
improvements thereon, and the proceeds of such Equipment; 

  
 6. 

 (d) Liens incurred in connection with the extension, renewal or refinancing of the indebtedness
secured by Liens of the type described in clauses (a) through (e) above, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness
being extended, renewed or refinanced does not increase; and 
 (e) Liens arising from judgments, decrees or attachments in circumstances
not constituting an Event of Default under Sections 8.4 (attachment) or 8.8 (judgments); and 
 (f) Liens in favor of other financial
institutions arising in connection with Borrower’s deposit accounts held at such institutions to secure standard fees for deposit services charged by, but not financing made available by such institutions, provided that Bank has a perfected
security interest in the amounts held in such deposit accounts. 
 “Permitted Transfer” means the conveyance, sale, lease, transfer or
disposition by Borrower or any Subsidiary of: 
 (a) Inventory in the ordinary course of business; 

(b) licenses and similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary course of business; 

(c) worn-out, surplus or obsolete Equipment not financed with the proceeds of Credit Extensions; 

(d) grants of security interests and other Liens that constitute Permitted Liens; and 
 (e) other assets of Borrower or its Subsidiaries that do not in the aggregate exceed $250,000 during any fiscal year. 
 “Person” means any individual, sole proprietorship, partnership, limited liability company, joint venture, trust, unincorporated organization, association, corporation, institution, public
benefit corporation, firm, joint stock company, estate, entity or governmental agency. 
 “Prime Rate” means the variable rate of
interest, per annum, most recently announced by Bank, as its “prime rate,” whether or not such announced rate is the lowest rate available from Bank. 
 “Responsible Officer” means each of the Chief Executive Officer, the Chief Operating Officer, the Chief Financial Officer and the Controller of Borrower. 

“Revolving Line” means a Credit Extension of up to $3,000,000 (inclusive of any amounts outstanding under the Ancillary Services Sublimit).

 “Revolving Maturity Date” means February 7, 2009. 
 “Schedule” means the schedule of exceptions attached hereto and approved by Bank, if any. 
 “SOS Reports” means the official reports from the Secretaries of State of each Collateral State, the state where Borrower’s chief executive office is located, the state of Borrower’s
formation and other applicable federal, state or local government offices identifying all current security interests filed in the Collateral and Liens of record as of the date of such report. 
 “Subordinated Debt” means any debt incurred by Borrower that is subordinated in writing to the debt owing by Borrower to Bank on terms reasonably acceptable to Bank (and identified as being such
by Borrower and Bank). 

  
 7. 

 “Subsidiary” means any corporation, partnership or limited liability company or joint venture in
which (i) any general partnership interest or (ii) more than 50% of the stock, limited liability company interest or joint venture of which by the terms thereof ordinary voting power to elect the Board of Directors, managers or trustees of
the entity, at the time as of which any determination is being made, is owned by Borrower, either directly or through an Affiliate. 

“Trademarks” means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and
like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks. 
 “Term
Advance(s)” means a cash advance or cash advances under the Term Loan. 
 “Term Loan” means a Credit Extension of up to
$4,500,000. 
 “Term Loan Maturity Date” means August 7, 2011. 
 “Tranche” means any of Tranche A or Tranche B. 
 “Tranche A” has the meaning
assigned in Section 2.1 (c)(i). 
 “Tranche B” has the meaning assigned in Section 2.1(c)(i). 

“Tranche A Advance” or “Tranche A Advances” means any Term Advances(s) made under Tranche A. 

“Tranche B Advance” or “Tranche B Advances” means any Term Advances(s) made under Tranche B. 

“Tranche A Availability End Date” means August 7, 2008. 
 “Tranche B Availability End Date” means February 7, 2009. 

  
 8. 

			
	DEBTOR	  	LIPOSCIENCE, INC.
		
	SECURED PARTY:	  	SQUARE 1 BANK

 EXHIBIT B

 COLLATERAL DESCRIPTION ATTACHMENT TO LOAN AND SECURITY AGREEMENT 

All personal property of Borrower (herein referred to as “Borrower” or “Debtor”) whether presently existing or hereafter created or
acquired, and wherever located, including, but not limited to: 
 (f) all accounts (including health-care-insurance receivables), chattel
paper (including tangible and electronic chattel paper), deposit accounts, documents (including negotiable documents), equipment (including all accessions and additions thereto), financial assets, general intangibles (including patents, trademarks,
copyrights, goodwill, payment intangibles and software), goods (including fixtures), instruments (including promissory notes), inventory (including all goods held for sale or lease or to be furnished under a contract of service, and including
returns and repossessions), investment property (including securities and securities entitlements), letter of credit rights, money, and all of Debtor’s books and records with respect to any of the foregoing, and the computers and equipment
containing said books and records; 
 (g) any and all cash proceeds and/or noncash proceeds of any of the foregoing, including, without
limitation, insurance proceeds, and all supporting obligations and the security therefor or for any right to payment. All terms above have the meanings given to them in the North Carolina Uniform Commercial Code, as amended or supplemented from time
to time, including revised Division 9 of the Uniform Commercial Code-Secured Transactions. 
 Notwithstanding the foregoing, the
Collateral shall not include any of the intellectual property, in any medium, of any kind or nature whatsoever, now or hereafter owned, licensed or acquired or received by Borrower, or in which Borrower now holds or hereafter acquires or receives
any right or interest (collectively, the “Intellectual Property”); provided, however, that the Collateral shall include all accounts and general intangibles that consist of rights to payment and proceeds from the sale, licensing or
disposition of all or any part, or rights in, the foregoing (the “Rights to Payment”). 
 Notwithstanding the
foregoing, if a judicial authority (including a U.S. Bankruptcy Court) holds that a security interest in the underlying Intellectual Property is necessary to have a security interest in the Rights to Payment, then the Collateral shall automatically,
and effective as of February 7, 2008, include the Intellectual Property to the extent and only to the extent necessary to permit perfection of Bank’s security interest in the Rights to Payment, and further provided, however, that
Bank’s enforcement rights with respect to any security interest in the Intellectual Property shall be absolutely limited to the Rights to Payment only, and Bank shall have no recourse whatsoever with respect to the underlying Intellectual
Property. 

  
 1. 

 EXHIBIT C 
 LOAN ADVANCE/PAYDOWN REQUEST FORM 
 DEADLINE FOR SAME DAY PROCESSING IS 5:30
P.M. Eastern Time* 
 FORMULA BASED LINES: DEADLINE FOR NEXT DAY PROCESSING IS 5:30 P.M. Eastern Time 

DEADLINE FOR WIRE TRANSFERS IS 4:30 P.M., Eastern Time  

*At month end and the day before a holiday, the cut off time is 1:30 P.M., Eastern Time 

**Subject to 3 day advance notice. 
  

																	
	 TO: Loan Analysis
	  	DATE:	  	TIME:
			
	 FAX #:
	  		  	

  

					
			
	FROM:	  	LIPOSCIENCE, INC.	  	TELEPHONE REQUEST (For Bank Use Only):
			
		  	Borrower’s Name	  	
			
	FROM:	  		  	The following person is authorized to request the loan payment transfer/loan advance on the designated account and is known to me.
			
		  	Authorized Signer’s Name	  	
			
	FROM:	  		  	
		  	Authorized Signature (Borrower)	  	 Authorized Request & Phone #

			
	PHONE #:	  		  	
			
		  		  	 Received by (Bank) & Phone #

			
	FROM ACCOUNT#:	  		  	
	 (please include Note number, if applicable)
 TO ACCOUNT #:
 (please include Note number, if applicable)
	  	 Authorized Signature (Bank)

  

																	
	REQUESTED TRANSACTION TYPE	  	REQUESTED DOLLAR AMOUNT	  	For Bank Use Only
			
	PRINCIPAL INCREASE* (ADVANCE)	  	$	  	Date Rec’d:
	PRINCIPAL PAYMENT (ONLY)	  	$	  	Time:
		  	Comp. Status:	  	YES	  	NO
	OTHER INSTRUCTIONS:	  	Status Date:
		  	Time:
		  	Approval:

 All representations and warranties
of Borrower stated in the Loan Agreement are true, correct and complete in all material respects as of the date of the telephone request for and advance confirmed by this Loan Advance/Paydown Request Form; provided, however, that those
representations and warranties the date expressly referring to another date shall be true, correct and complete in all material respects as of such date. 
  

																	
			
	*IS THERE A WIRE REQUEST TIED TO THIS LOAN ADVANCE? (PLEASE CIRCLE ONE)	  	YES	  	NO

 If YES, the Outgoing
Wire Transfer Instructions must be completed below. 
  

																	
			
	OUTGOING WIRE TRANSFER INSTRUCTIONS	  	Fed Reference Number	  	Bank Transfer Number

The items marked with an asterisk (*) are required to be completed. 

 

			
	 *Beneficiary Name
	  	
	 *Beneficiary Account Number
	  	
	 *Beneficiary Address
	  	
	 Currency Type
	  	US DOLLARS ONLY
	 *ABA Routing Number (9 Digits)
	  	
	 *Receiving Institution Name
	  	
	 *Receiving Institution Address
	  	
	 *Wire Account
	  	$

  
 2. 

 EXHIBIT D 
 BORROWING BASE CERTIFICATE 
 [Please refer to New Borrower Kit]

  
 1. 

 EXHIBIT E 
 COMPLIANCE CERTIFICATE 
 [Please refer to New Borrower Kit]

  
 1. 

 FIRST AMENDMENT 

TO  

LOAN AND SECURITY AGREEMENT 
 This First Amendment to Loan and Security Agreement is entered into as of April 7, 2009 (the “Amendment”) by and between SQUARE 1 BANK (“Bank”) and LIPOSCIENCE, INC.
(“Borrower”). 
 RECITALS 
 Borrower and Bank are parties to that certain Loan and Security Agreement dated as of February 7, 2008, as may be amended from time to time (the “Agreement”). The parties desire to amend
the Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 

1. This Amendment shall be effective as of February 7, 2009. 

2. The following defined terms in Exhibit A to the Agreement are amended to read as follows: 

“Ancillary Services” means any of the following products or services requested by Borrower and approved by Bank
under the Revolving Line, including, without limitation, Letters of Credit, or other treasury management services. 
 “Ancillary Services Sublimit” means a sublimit for Ancillary Services under the Revolving Line not to exceed $350,000 for a Letter of Credit to support Borrower’s credit cards. 

“Revolving Loan Maturity Date” means February 7, 2010. 

3. Clause (g) in the defined term “Permitted Investments” in Exhibit A to the Agreement is amended to read as
follows: 
 “(g) Investments in unfinanced capital expenditures in each of the fiscal years 2009 and 2010,
not to exceed $2,000,000.” 
 4. Sections 2.1(b)(iii) and (iv) of the Agreement are hereby amended in their
entirety and restated to read as follows: 
 (iii) Ancillary Services Sublimit. Subject to the
availability under the Revolving Line, at any time and from time to time from the date hereof through the Business Day immediately prior to the Revolving Maturity Date, Borrower may request the provision of Ancillary Services from Bank. The
aggregate limit of the Ancillary Services shall not exceed the Ancillary Services Sublimit, provided that availability under the Revolving Line shall be reduced by the aggregate limits of any outstanding and undrawn amounts under all Letters of
Credit issued hereunder. In addition, Bank may, in its sole discretion, charge as Advances any amounts for which Bank becomes liable to third parties in connection with the provision of the Ancillary Services. The terms and conditions (including
repayment and fees) of such Ancillary Services shall be subject to the terms and conditions of the Bank’s standard forms of application and agreement for the applicable Ancillary Services, which Borrower hereby agrees to execute. 

(iv) Collateralization of Obligations Extending Beyond Maturity. If Borrower has not secured to Bank’s
satisfaction its obligations with respect to any Letters of Credit by the Revolving Maturity Date, then, effective as of such date, the balance in any deposit accounts held by Bank and the certificates of deposit or time deposit accounts issued by
Bank in Borrower’s name (and any interest paid thereon or proceeds thereof, including any amounts payable upon the maturity or liquidation of such certificates or accounts), shall automatically secure such obligations to the extent of the then
continuing or outstanding and undrawn Letters of Credit. Borrower authorizes Bank to hold such balances in pledge and to decline to honor any drafts thereon or any requests by Borrower or any other Person to pay or otherwise transfer any part of
such balances for so long as the Letters of Credit are outstanding or continue. 

  
 1 

 5. Section 2.3(a) of the Agreement is hereby amended in its entirety and
restated to read as follows: 
 (a) Interest Rates. 

(i) Advances. Except as set forth in Section 2.3(b), the Advances shall bear interest, on the outstanding
daily balance thereof, at a variable annual rate equal to the greater of (x) 3.25% above the Prime Rate then in effect, or (y) 6.75%. 
 (ii) Term Loans. Except as set forth in Section 2.3(b), the Term Loans shall bear interest, on the outstanding daily balance thereof, at a variable rate equal to the greater of (x) 3.75%
above the Prime Rate then in effect on the date of each such Term Loan, or (y) 7.25%. 
 6. Section 6.8 of the
Agreement is hereby amended in its entirety and restated to read as follows: 
 6.8 Milestone Covenants.

 (a) Borrower shall have filed a 510k application with the United States Food and Drug Administration
for the Numera machine on or before November 30, 2009, such filing to be confirmed to Bank by Borrower’s President and Chief Executive Officer and Board Member from Three Arch Partners. 

(b) Borrower shall have received 510k clearance from the United States Food and Drug Administration on or before
May 31, 2010 to market the Numera machine, such receipt to be confirmed to Bank by Borrower’s President and Chief Executive Officer and Board Member from Three Arch Partners. 

7. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The
Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance
of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements
entered into in connection with the Agreement, in each case, as amended hereby. 
 8. Borrower represents and warrants
that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment, other than (i) to the extent such representations and warranties expressly relate to an earlier date, which
representations and warranties are true and correct as of such date; and (ii) for those changes to the representations and warranties resulting from events, occurrences or circumstances pertaining to the Borrower’s business and permitted
under the Agreement and other Loan Documents, as amended by this Agreement. 
 9. This Amendment may be executed in two
or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. 

10. As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank,
the following: 
 (a) this Amendment, duly executed by Borrower; 

(b) a certificate of the Borrower with respect to incumbency and resolutions authorizing the execution and delivery of
this Amendment; 

  
 2 

 (c) a renewal/amendment fee in the amount of $17,500 plus an amount equal to
all reasonable Bank Expenses incurred through the date of this Amendment not to exceed the amount of $5,000; and 

(d) such other documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 3 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above
written. 
  

			
	LIPOSCIENCE, INC.
		
	By:	 	/s/ Lucy G. Martindale
	Title:	 	Chief Financial Officer

  

			
	SQUARE 1 BANK
		
	By:	 	/s/ Illegible
	Title:	 	VP

  
 4 

 SECOND AMENDMENT 

TO 

LOAN AND SECURITY AGREEMENT 
 This Second Amendment to Loan and Security Agreement is entered into as of December 4, 2009 (the “Amendment”) by and between SQUARE 1 BANK (“Bank”) and LIPOSCIENCE, INC.
(“Borrower”). 
 RECITALS 
 Borrower and Bank are parties to that certain Loan and Security Agreement dated as of February 7, 2008, as may be amended from time to time (the “Agreement”). The parties desire to amend
the Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 

1. Section 6.8 of the Agreement is hereby amended and restated as follows:  

6.8 Milestone Covenants. 
 (a) Bonower shall have filed a 510k application with the United States Food and Drug Administration for the Numera machine on or before April 30, 2010, such filing to be confirmed to Bank by
Borrower’s President and Chief Executive Officer and Board Member from Three Arch Partners. 
 (b)
Borrower shall have received 510k clearance from the United States Food and Drug Administration on or before October 31, 2010 to market the Numera machine, such receipt to be confìrmed to Bank by Borrower’s President and Chief
Executive Officer and Board Member from Three Arch Partners. 
 2. Unless otherwise defined, all initially capitalized
terms in this Amendment shall be as defined in the Agreement. The Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as
expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower
ratifres and reaffirms the continuing effectiveness of all agreements entered into in connection with the Agreement, in each case, as amended hereby. 
 3. Borrower represents and warrants that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment. 

4. This Amendment may be executed in two or more counterpads, each of which shall be deemed an original, but all of which together
shall constitute one instrument. 
 5. As a condition to the effectiveness of this Amendment, Bank shall have received,
in form and substance satisfactory to Bank, the following: 
 a) this Amendment, duly executed by Borrower;

 b) all Bank Expenses incurred through the date of this Amendment, which may be debited from any of
Borrower’s accounts; 

 c) an Amendment Fee of $12,300, which may be debited from any of
Borrower’s accounts; and 
 d) such other documents and completion of such other
matters, as Bank may reasonably deem necessary of
appropriate. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above
written. 
  

			
	LIPOSCIENCE, INC.
		
	By:	 	/s/ Lucy G. Martindale
	Title:	 	Chief Financial Officer

  

			
	SQUARE 1 BANK
		
	By:	 	/s/ Mara Huntington
	Title:	 	Vice President

 THIRD AMENDMENT 

TO 

LOAN AND SECURITY AGREEMENT 
 This Third Amendment to Loan and Security Agreement is entered into as of May 7, 2010 (the “Amendment”) by and between SQUARE 1 BANK (“Bank”) and LIPOSCIENCE, INC.
(“Borrower”). 
 RECITALS 
 Borrower and Bank are parties to that certain Loan and Security Agreement dated as of February 7, 2008, as may be amended from time to time (the “Agreement”). The parties desire to amend
the Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 

1. Bank hereby waives Borrower’s violation of the Milestone Covenant, as set forth in Section 6.8(a) of the Agreement,
for Borrower’s failure to receive acceptance of its 510k application for the Numera machine by the United States Food and Drug Administration on or before April 30, 2010. 

2. Section 6.7 of the Agreement is hereby amended and restated, as follows: 

6.7 Financial Covenants. Borrower shall at all times maintain the following financial ratios and covenants:

 (a) Liquidity Ratio. A Liquidity Ratio of at least 1.25 lo 1.00, measured monthly. 

(b) Revenue to Plan. Measured monthly, beginning with the monthly reporting period ending May 31, 2010 and
continuing through the monthly reporting period ending December 31, 2010, Revenue shall be at least 75.0% of the projections that have been approved by Borrower’s Board of Directors, such required amounts being set forth in column B of the
table immediately below for the corresponding monthly reporting periods. For 2011 fiscal year, Bank shall determine new Revenue covenant levels based upon the projections approved by Borrower’s Board of Directors, which shall be provided to
Bank in accordance with Section 6.2(iii) of the Agreement. 
  

					
	 A
	  	B	 
	 Monthly Reporting
 Period
	  	Revenue to Plan
covenant levels	 
	 May 2010
	  	$	2,405,369	  
	 June 2010
	  	$	2,588,300	  
	 July 2010
	  	$	2,625,122	  
	 August 2010
	  	$	2,734,209	  
	 September 2010
	  	$	2,650,166	  
	 October 2010
	  	$	2,765,940	  
	 November 2010
	  	$	2,894,216	  
	 December 2010
	  	$	2,964,407	  

 3. Section 6.8 of the Agreement is hereby deleted, and the remaining subsections
of Section 6, and any references to such subsections in the Agreement, are hereby renumbered accordingly. 
 4. The
following definitions in Exhibit A to the Agreement are hereby added or amended and restated, as follows: 

“Revenue” means revenue recognized in accordance with GAAP. 

“Revolving Maturity Date” means May 6, 2011. 

5. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The
Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance
of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements
entered into in connection with the Agreement, in each case, as amended hereby. 
 6. Borrower represents and warrants
that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment. 

7. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one instrument. 
 8. As a condition to the effectiveness of this Amendment, Bank shall have
received, in form and substance satisfactory to Bank, the following: 
 a) this Amendment, duly executed by
Borrower; 
 b) payment of $6,000 Facility Fee, which may be debited from any of Borrower’s account;

 e) payment of all Bank Expenses, including Bank’s expenses for the documentation of this Amendment and
any related documents, and any UCC, good standing or intellectual property search or filing fees, which may be debited from any of Borrower’s accounts; and 
 d) such other documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate. 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above
written. 
  

									
	LIPOSCIENCE, INC.	 		 	SQUARE 1 BANK
					
	By:	 	/s/ Lucy G. Martindale	 		 	By:	 	/s/ Mara Huntington
	Title:	 	Chief Financial Officer	 		 	Title:	 	VP

 FOURTH AMENDMENT 

TO 

LOAN AND SECURITY AGREEMENT 
 This Fourth Amendment to Loan and Security Agreement is entered into as of March 31, 2011 (the “Amendment”) by and between SQUARE 1 BANK (“Bank”) and LIPOSCIENCE, INC.
(“Borrower”). 
 RECITALS 
 Borrower and Bank are parties to that certain Loan and Security Agreement dated as of February 7, 2008, as may be amended from time to time (the “Agreement”). The parties desire to amend
the Agreement in accordance with the terms of this Amendment. 
 NOW, THEREFORE, the parties agree as follows: 

1. Bank and Borrower hereby confirm that Section 6.8 of the Agreement is titled “Consent of Inbound Licensors” and
Section 6.9 of the Agreement is titled “Further Assurances”. 
 2. A new Section 2.1(d) is hereby
added to the Agreement, as follows: 
 (d) Term Loan A. 

(i) Subject to and upon the terms and conditions of this Agreement, Bank agrees to make one (1) term loan to
Borrower in an aggregate principal amount of Six Million Dollars ($6,000,000) (the “Term Loan A”). Borrower hereby requests that the Bank make the Term Loan A on or about March 31, 2011. The proceeds of the Term Loan A shall be used
first to repay any and all Term Advances outstanding under the Term Loan, and second for general working capital purposes and for capital expenditures. 

(ii) Interest shall accrue from the date of the Term Loan A at the rate specified in Section 2.3(a) and prior
to the Term Loan A Interest Only End Date shall be payable monthly beginning on the last day of the month next following the Term Loan A, and continuing on the same day of each month therereafter. If the Term Loan A is outstanding on the Term Loan A
Interest Only End Date it shall be payable in 30 equal monthly installments of principal, plus all accrued interest, beginning on January 31, 2012 and continuing on the last day of each month thereafter through the Term Loan A Maturity Date, at
which time all amounts due in connection with the Term Loan A and any other amounts due under this Agreement shall be immediately due and payable. The Term Loan A, once repaid, may not be reborrowed. Borrower may prepay the Term Loan A without
penalty or premium. 
 3. Section 2.3(a) of the Agreement is hereby amended and restated, as follows: 

(a) Interest Rates. 

(i) Advances. Except as set forth in Section 2.3(b), the Advances shall bear interest, on the outstanding
daily balance thereof, at a variable annual rate equal to the greater of (x) 3.00% above the Prime Rate then in effect, or (y) 6.25%. 

  

					
	LipoScience, Inc. – 4th Amendment to LSA	  	1	  	

 (ii) Term Loans. Except as set forth in Section 2.3(b), the Term
Loans shall bear interest, on the outstanding daily balance thereof, at a variable annual rate equal to the greater of (x) 3.75% above the Prime Rate then in effect on the date of each such Term Loan, or (y) 7.25%. 

(iii) Term Loan A. Except as set forth in Section 2.3(b), the Term Loan A shall bear interest, on the
outstanding daily balance thereof, at a variable annual rate equal to the greater of (x) 3.75% above the Prime Rate then in effect, or (y) 7.25%. 
 4. Subsection 6.2(ii) of the Agreement is hereby amended and restated, as follows: 
 (ii) as soon as available, but in any event within 180 days after the end of Borrower’s fiscal year, audited (or an opinion qualified for going concern provided that Borrower’s existing
investors provide additional equity as needed) consolidated and consolidating financial statements of Borrower prepared in accordance with GAAP, consistently applied, together with an opinion which is either unqualified, qualified only for going
concern so long as Borrower’s investors provide additional equity as needed or otherwise consented to in writing by Bank on such financial statements of an independent certified public accounting firm reasonably acceptable to Bank; 

5. A new Section 6.2(d) is hereby added to the Agreement, as follows: 

(d) Borrower shall promptly deliver to Bank a summary of all material correspondence between the Borrower and the United
States Food and Drug Administration with respect to the application for the Vantera system (formerly referred to as the Numera system), such summary to be in the same form as provided to Borrower’s Board of Directors. 

6. A new Section 6.2(e) is hereby added to the Agreement, as follows: 

(e) On March 31, 2012 and each annual anniversary thereafter, Borrower shall deliver to Bank a report outlining the
location of all Vantera machines. 
 7. Section 6.7(b) of the Agreement is hereby amended and restated, as follows:

 (b) Revenue to Plan. Measured monthly, beginning with the reporting period ending January 31, 2011
and continuing through the reporting period ending December 31, 2011, Revenue shall be at least 75.0% of the projections that have been approved by Borrower’s Board of Directors, such required amounts being set forth in column B of the
table immediately below for the corresponding monthly reporting periods. For the 2012 fiscal year, Bank shall determine new Revenue covenant levels acting in good faith and on a reasonable basis and based upon the projections approved by
Borrower’s Board of Directors, which shall be provided to Bank in accordance with Section 6.2(iii) of the Agreement. 

  

					
	Liposcience, Inc. – 4th Amendment to LSA	  	2	  	

					
	 A
	  	B	 
	 Monthly Reporting
 Period
	  	Revenue to Plan
covenant levels	 
	 January 2011
	  	$	2,419,961	  
	 February 2011
	  	$	2,576,088	  
	 March 2011
	  	$	2,810,278	  
	 April 2011
	  	$	2,553,658	  
	 May 2011
	  	$	2,718,411	  
	 June 2011
	  	$	2,965,539	  
	 July 2011
	  	$	2,713,821	  
	 August 2011
	  	$	2,888,907	  
	 September 2011
	  	$	3,151,535	  
	 October 2011
	  	$	2,889,372	  
	 November 2011
	  	$	3,075,783	  
	 December 2011
	  	$	3,355,400	  

 8. A new
Section 6.10 is hereby added to the Agreement, as follows: 
 6.10 Milestone Covenant. Borrower shall
have filed the final 510k approval application for Vantera with the United States Food and Drug Administration on or before December 31, 2011, such filing to be confirmed to Bank by Borrower’s Board of Directors. 

9. Section 7.2 of the Agreement is hereby amended and restated, as follows: 

7.2 Change in Name, Location, Executive Office, or Executive Management; Change in Business; Change in
Fiscal Year; Change in Control. Change its name or the state of Borrower’s incorporation or relocate its chief executive office without 30 days prior written notification to Bank; replace its chief executive officer or chief financial
officer without 30 days prior written notification to Bank; suffer the resignation of one or more directors from its board of directors in anticipation of the Borrower’s insolvency, in either case without the prior written consent of Bank which
may be withheld in Bank’s sole discretion; engage in any business, or permit any of its Subsidiaries to engage in any business, other than or reasonably related or incidental to the businesses currently engaged in by Borrower; change its fiscal
year end; have a Change in Control. 
 10. Section 7.11 of the Agreement is hereby amended and restated, as follows:

 7.11 Reserved. 
 11. The following definitions in Exhibit A to the Agreement are hereby added, or amended and restated, as follows: 

“Credit Extension” means each Advance, Term Advance, Term Loan A, Ancillary Service, or any other extension of
credit by Bank to or for the benefit of Borrower hereunder. 

  

					
	Liposcience, Inc. – 4th Amendment to LSA	  	3	  	

 “Revolving Line” means a Credit Extension of up to $4,000,000
(inclusive of any amounts outstanding under the Ancillary Services Sublimit). 
 “Revolving Maturity
Date” means March 29, 2012. 
 “Term Loan A Interest Only End Date” means December 31,
2011. 
 “Term Loan A Maturity Date” means June 30, 2014. 

12. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Agreement. The
Agreement, as amended hereby, shall be and remain in full force and effect in accordance with its respective terms and hereby is ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance
of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Bank under the Agreement, as in effect prior to the date hereof. Borrower ratifies and reaffirms the continuing effectiveness of all agreements
entered into in connection with the Agreement, in each case, as amended hereby. 
 13. Borrower represents and warrants
that the representations and warranties contained in the Agreement are true and correct as of the date of this Amendment. 

14. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one instrument. 
 15. As a condition to the effectiveness of this Amendment, Bank shall have
received, in form and substance satisfactory to Bank, the following: 
 a) this Amendment, duly executed by
Borrower; 
 b) payment of $20,000 Facility Fee, which may be debited from any of Borrower’s accounts;

 c) a Second Warrant to purchase stock, duly executed by Borrower; 

d) an officer’s certificate of Borrower with respect to incumbency and resolutions authorizing the execution and
delivery of this Amendment; 
 e) payment of all Bank Expenses, including Bank’s expenses for the
documentation of this Amendment and any related documents, and any UCC, good standing or intellectual property search or filing fees, which may be debited from any of Borrower’s accounts; and 

f) such other documents and completion of such other matters, as Bank may reasonably deem necessary or appropriate.

  

					
	Liposcience, Inc. – 4th Amendment to LSA	  	4	  	

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the first date above written.

  

									
	LIPOSCIENCE, INC.	 		 	SQUARE 1 BANK
					
	By:	 	/s/ Lucy G. Martindale	 		 	By:	 	/s/ Mara Huntington
	Name:	 	Lucy G. Martindale	 		 	Name:	 	Mara Huntington
	Title:	 	Chief Financial Officer	 		 	Title:	 	SVP

 [Signature Page to Fourth Amendment
to Loan and Security Agreement] 

  

					
	Liposcience, Inc. – 4th Amendment to LSA	  	5Exhibit 10.2

 Exhibit 10.2 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR ANY STATE SECURITIES LAWS, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONECTION
WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH LAWS RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 OR ANY APPLICABLE STATE SECURITIES LAWS. 
  

 
 STOCK PURCHASE WARRANT

 To Subscribe for and Purchase 
 Series F Convertible Preferred Stock of LipoScience, Inc. 
 LIPOSCIENCE,
INC. 
 THIS CERTIFIES THAT, for value received, Piper Jaffray & Co. (herein called “Purchaser”), or
registered assigns, is entitled to subscribe for and purchase from LipoScience, Inc. (herein called the “Company”), a corporation organized and existing under the laws of the State of Delaware, at the price specified below (subject to
adjustment as noted below) at any time after the date hereof to and including seven (7) years from the date of issuance (the “Expiration Date”), Forty-One Thousand Three Hundred Seventy-Nine (41,379) fully paid and nonassessable
shares of Series F Convertible Preferred Stock (herein the “Preferred Stock”) (subject to adjustment as noted below). This Warrant has been issued pursuant to an Engagement Agreement dated as of January 13, 2006 (the
“Agreement”) between the Purchaser and the Company. 
 The warrant purchase price (subject to adjustment as noted
below) shall be $4.35 per share. 
 This Warrant is subject to the following provisions, terms and conditions: 

1. The rights represented by this Warrant may be exercised by the holder hereof, in whole or in part, by written notice of exercise
delivered to the Company and by the surrender of this Warrant (properly endorsed if required) at the principal office of the Company and upon payment to it by check of the purchase price for such shares. The Company agrees that the shares so
purchased shall be and are deemed to be issued to the holder hereof as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment made for such shares as aforesaid. Subject
to the provisions of the next succeeding paragraph, certificates for the shares of stock so purchased shall be delivered to the holder hereof within a reasonable time, not exceeding 10 days, after the rights represented by this Warrant shall have
been so exercised, and, unless this Warrant has expired, a new Warrant representing the number of shares, if any, with respect to which this Warrant shall not then have been exercised shall also be delivered to the holder hereof within such time.

 2. Notwithstanding the foregoing, however, the Company shall not be required to deliver any
certificate for shares of stock upon exercise of this Warrant except in accordance with the provisions, and subject to the limitations, of paragraph 8 hereof and the restrictive legend under the heading “Restriction on Transfer” below.

 3. The Company represents and warrants that this Warrant has been duly authorized by all necessary corporate action, has been
duly executed and delivered and is a legal and binding obligation of the Company. The Company covenants and agrees that all shares which may be issued upon the exercise of the rights represented by this Warrant according to the terms hereof or
represented by the Preferred Stock will, upon issuance, be duly authorized and issued, fully paid and nonassessable. The Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised
or the Preferred Stock may be converted into Common Stock of the Company (“Common Stock”), the Company will at all times have authorized, and reserved for the purpose of issue or transfer upon exercise of the subscription rights evidenced
by this Warrant or conversion of the Preferred Stock, a sufficient number of shares of its Preferred Stock or Common Stock to provide for the exercise of the rights represented by this Warrant or the Preferred Stock. 

4. The above provisions are, however, subject to the following: 
 (a) The warrant purchase price shall, from and after the date of issuance of this Warrant, be subject to adjustment from time to time as hereinafter provided. Upon each adjustment of the warrant purchase
price, the holder of this Warrant shall thereafter be entitled to purchase, at the warrant purchase price resulting from such adjustment, the number of shares obtained by multiplying the warrant purchase price in effect immediately prior to such
adjustment by the number of shares purchasable pursuant hereto immediately prior to such adjustment and dividing the product thereof by the warrant purchase price resulting from such adjustment. 

(b) In case the Company shall (i) declare a dividend upon the Preferred Stock payable in Preferred Stock (other than a dividend
declared to effect a subdivision of the outstanding shares of Preferred Stock, as described in subparagraph (c) below) or any obligations or any shares of stock of the Company which are convertible into or exchangeable for Preferred Stock (such
obligations or shares of stock being hereinafter referred to as “Convertible Securities”), or in any rights or options to purchase any Preferred Stock or Convertible Securities, or (ii) declare any other dividend or make any other
distribution upon the Preferred Stock payable otherwise than out of earnings or earned surplus, then thereafter the holder of this Warrant upon the exercise hereof will be entitled to receive the number of shares of Preferred Stock to which such
holder shall be entitled upon such exercise, and, in addition and without further payment therefor, such number of shares of Preferred Stock, such that upon exercise hereof, such holder would receive such number of shares of Preferred Stock as a
result of each dividend described in clause (i) above and each dividend or distribution described in clause (ii) above which such holder would have received by way of any such dividend or distribution if continuously since the record date
for any such dividend or distribution such holder (i) had been the record holder of the number of shares of Preferred Stock then received, and (ii) had retained all dividends or distributions in stock or securities (including

  
 -2-

 
Preferred Stock or Convertible Securities, or in any rights or options to purchase any Preferred Stock or Convertible Securities) payable in respect of such Preferred Stock or in respect of any
stock or securities paid as dividends or distributions and originating directly or indirectly from such Preferred Stock. For the purposes of the foregoing, a dividend or distribution other than in cash shall be considered payable out of earnings or
surplus only to the extent that such earnings or surplus are charged an amount equal to the fair value of such dividend as determined by the Board of Directors of the Company. 
 (c) In case the Company shall at any time subdivide its outstanding shares of Preferred Stock into a greater number of shares, the warrant purchase price in effect immediately prior to such subdivision
shall be proportionately reduced, and conversely, in case the outstanding shares of Preferred Stock of the Company shall be combined into a smaller number of shares, the warrant purchase price in effect immediately prior to such combination shall be
proportionately increased. 
 (d) If any capital reorganization or reclassification of the capital stock of the Company, or
consolidation or merger of the Company with another corporation, or the sale of all or substantially all of its assets to another corporation shall be effected in such a way that holders of Preferred Stock shall be entitled to receive stock,
securities or assets with respect to or in exchange for Preferred Stock, then, as a condition of such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision shall be made whereby the holder hereof shall
thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in this Warrant and in lieu of the shares of the Preferred Stock of the Company immediately theretofore purchasable and receivable upon the
exercise of the rights represented hereby, such shares of stock, securities or assets as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Preferred Stock equal to the number of shares of such stock
immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby had such reorganization, reclassification, consolidation, merger or sale not taken place, and in any such case appropriate provision shall be made
with respect to the rights and interests of the holder of this Warrant to the end that the provisions hereof (including without limitation provisions for adjustments of the warrant purchase price and of the number of shares purchasable upon the
exercise of this Warrant) shall thereafter be applicable, as nearly as may be, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The Company shall not effect any such consolidation, merger or
sale, unless prior to the consummation thereof the successor corporation (if other than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall assume, by written instrument executed and mailed to the
registered holder hereof at the last address of such holder appearing on the books of the Company, the obligation to deliver to such holder such shares of stock, securities or assets as, in accordance with the foregoing provisions, such holder may
be entitled to purchase. 
 (e) If by reason of the terms of the Company’s Certificate of Incorporation, all of the
Company’s outstanding Preferred Stock shall have been mandatorily redeemed for cash or mandatorily converted into shares of Common Stock (either such event being herein referred to as 

  
 -3-

 
an “Event”), then from and after such Event, the holder of this Warrant shall have the right to purchase and receive in lieu of the shares of Preferred Stock immediately theretofore
purchasable and receivable hereunder that number of shares of Common Stock equal to the number of shares of Common Stock, subject to adjustment as herein provided, that would have been received if this Warrant had been exercised in full and the
Preferred Stock received thereupon had been simultaneously converted into shares of Common Stock immediately prior to such Event. The warrant purchase price shall be immediately adjusted to equal (subject to further adjustment as herein provided)
the quotient obtained by dividing (x) the aggregate warrant purchase price of the maximum number of shares of Preferred Stock for which this Warrant was exercisable immediately prior to such Event, by (y) the number of shares of Common
Stock for which this Warrant is exercisable immediately after such Event. From and after such Event, references in this Warrant to Preferred Stock shall be deemed amended to be references to Common Stock, and any other appropriate provision shall be
made, to the extent necessary or appropriate, to accord the holder of this Warrant the same rights and privileges relative to the purchase of Common Stock as this Warrant accorded the holder relative to the purchase of Preferred Stock prior to the
Event (including without limitation the provisions for adjustments of the warrant purchase price and of the number of shares purchasable upon exercise of this Warrant). 
 (f) Upon any adjustment of the warrant purchase price, then and in each such case the Company shall give written notice thereof, by first-class mail, postage prepaid, addressed to the registered holder of
this Warrant at the address of such holder as shown on the books of the Company, which notice shall state the warrant purchase price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such
price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. 
 (g) In case any time: 
 (1) the Company shall declare any cash
dividend on its capital stock at a rate in excess of the rate of the last cash dividend theretofore paid; 
 (2)
the Company shall pay any dividend payable in stock upon its capital stock or make any distribution (other than regular cash dividends) to the holders of its capital stock; 

(3) the Company shall offer for subscription pro rata to the holders of its capital stock any additional shares of stock
of any class or other rights; 
 (4) there shall be any capital reorganization, or reclassification of the
capital stock of the Company, or consolidation or merger of the Company with, or sale of all or substantially all of its assets to, another corporation; 
 (5) there shall be a voluntary or involuntary dissolution, liquidation or winding up of the Company; or 

  
 -4-

 (6) there shall be any redemption or mandatory conversion of Preferred
Stock; 
 then, in any one or more of said cases, the Company shall give written notice, by first-class mail, postage prepaid, addressed to the
registered holder of this Warrant at the address of such holder as shown on the books of the Company, of the date on which (aa) the books of the Company shall close or a record shall be taken for such dividend, distribution or subscription rights,
or (bb) such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding up, or conversion or redemption shall take place, as the case may be. Such notice shall also specify the date as of which the holders of
capital stock of record shall participate in such dividend, distribution or subscription rights, or shall be entitled to exchange their capital stock for securities or other property deliverable upon such reorganization, reclassification,
consolidation, merger, sale, dissolution, liquidation or winding up, or conversion or redemption, as the case may be. Such written notice shall be given at least 15 days prior to the action in question and not less than 15 days prior to the record
date or the date on which the Company’s transfer books are closed in respect thereto. 
 (h) If any event occurs as to
which in the opinion of the Board of Directors of the Company the other provisions of this paragraph 4 are not strictly applicable or if strictly applicable would not fairly protect the purchase rights of the holder of this Warrant or of Preferred
Stock in accordance with the essential intent and principles of such provisions, then the Board of Directors shall make an adjustment in the application of such provisions, in accordance with such essential intent and principles, so as to protect
such purchase rights as aforesaid. 
 (i) No fractional shares of Preferred Stock shall be issued upon the exercise of this
Warrant, but, instead of any fraction of a share which would otherwise be issuable, the Company shall pay a cash adjustment (which may be effected as a reduction of the amount to be paid by the holder hereof upon such exercise) in respect of such
fraction in an amount equal to the same fraction of the Market Price per share of Preferred Stock as of the close of business on the date of the notice required by paragraph g above. “Market Price” shall mean, if the Preferred Stock is
traded on a securities exchange, the average of the closing prices of the Preferred Stock on such exchange on the 20 trading days ending on the trading day prior to the date of determination, or, if the Preferred Stock is otherwise traded in the
over-the-counter market, the average of the closing bid prices on the 20 trading days ending on the trading day prior to the date of determination. If at any time the Preferred Stock is not traded on an exchange, or otherwise traded in the
over-the-counter market, but the Common Stock of the Company is, then the Market Price shall be deemed to be the average closing prices or average closing bid prices of the Common Stock, as the case may be, or, if such exercise occurs in connection
with a public offering of the Common Stock, the public offering price of the Common Stock, in each case, multiplied by the number of shares or fraction thereof into which a share of Preferred Stock is then convertible. If at any time neither the
Preferred Stock nor the Common Stock is traded on an exchange or the NASDAQ National Market System, or otherwise traded in the over-the-counter market, the Market Price shall be deemed to be the fair value thereof determined in good faith by the
Board of Directors of the Company as of a date which is within 15 days of the date as of which the determination is to be made. 

  
 -5-

 5. This Warrant shall not entitle the holder hereof to any voting rights or other rights as
a stockholder of the Company. 
 6. The Company hereby grants registration rights to the holder of this Warrant for any Common
Stock of the Company obtained upon conversion of the Preferred Stock, comparable to the registration rights granted to the investors in that certain Second Amended and Restated Investor Rights Agreement, dated as of August
        , 2006, as amended (the “Investor Rights Agreement”), with the following exceptions and clarifications: 

(i) The holder will have no demand registration rights as set forth in Section 2.2 of the Investor Rights Agreement,
but can otherwise participate in any registration demanded by the Investors thereunder, subject to underwriting cutbacks as set forth in Section 2.3(b). 
 (ii) The holder will be subject to the same provisions regarding indemnification and Market Stand-off as contained in Sections 2.7 and 2.13 of the Investor Rights Agreement. 

(iii) The registration rights are freely assignable by the holder of this Warrant in connection with a permitted transfer
of this Warrant or the Preferred Stock issued upon the exercise hereof. 
 7. The holder of this Warrant represents and warrants
that: 
 (a) This Warrant and the shares issuable upon exercise thereof are being acquired for its own account, for investment
and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act of 1933 (the “Act”). 
 (b) The holder of this Warrant understands that this Warrant and the shares issuable hereunder have not been registered under the Act or any state securities laws by reason of their issuance in a
transaction exempt from the registration and prospectus delivery requirements of the Act pursuant to section 4(2) thereof, and that they must be held by such holder indefinitely, and that such holder must therefore bear economic risk of such
investment indefinitely, unless a disposition thereof is registered under the Act or applicable state securities laws or is otherwise exempted from such registration. 
 (c) The holder of this Warrant has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of acquiring and holding this Warrant and the
shares issuable hereunder and of protecting its interests in connection therewith. The holder of this Warrant is an “accredited investor” within the meaning of Section 501 of Regulation D promulgated under the Act. 

  
 -6-

 (d) The holder of this Warrant is able to bear the economic risk of acquiring the shares
issuable hereunder pursuant to the terms of this Warrant. 
 8. The holder of this Warrant, by acceptance hereof, agrees to give
written notice to the Company before transferring or assigning this Warrant or transferring any Preferred Stock issuable or issued upon the exercise hereof of such holder’s intention to do so, describing briefly the manner of any proposed
transfer or assignment of this Warrant or such holder’s intention as to the disposition to be made of shares of Preferred Stock issuable or issued upon the exercise hereof. Such holder shall also provide the Company with an opinion of counsel
satisfactory to the Company to the effect that the proposed transfer or assignment of this Warrant or disposition of shares may be effected without registration or qualification (under any Federal or State law) of this Warrant or the shares of
Preferred Stock issuable or issued upon the exercise hereof. Upon receipt of such written notice and opinion by the Company, such holder shall be entitled to transfer or assign this Warrant, or to exercise this Warrant in accordance with its terms
and dispose of the shares received upon such exercise or to dispose of shares of Preferred Stock received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered by such holder to the Company, provided
that an appropriate legend respecting the aforesaid restrictions on transfer and disposition may be endorsed on this Warrant or the certificates for such shares. 
 9. Subject to the provisions of paragraph 8 hereof, this Warrant and all rights hereunder are transferable, in whole or in part, at the principal office of the Company by the holder hereof in person or by
duly authorized attorney, upon surrender of this Warrant properly endorsed. Each taker and holder of this Warrant, by taking or holding the same, consents and agrees that the bearer of this Warrant, when endorsed, may be treated by the Company and
all other persons dealing with this Warrant as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Warrant, subject to the terms and restrictions hereof, or to the transfer hereof on the
books of the Company, any notice to the contrary notwithstanding; but until such transfer on such books, the Company may treat the registered holder hereof as the owner for all purposes. 

10. This Warrant is exchangeable, upon the surrender hereof by the holder hereof at the principal office of the Company, for new Warrants
of like tenor representing in the aggregate the right to subscribe for and purchase the number of shares which may be subscribed for and purchased hereunder, each of such new Warrants to represent the right to subscribe for and purchase such number
of shares as shall be designated by said holder hereof at the time of such surrender. 
 11. (a) In addition to and without
limiting the rights of the holder of this Warrant under the terms of this Warrant, the holder of this Warrant shall have the right (the “Conversion Right”) to convert this Warrant or any portion thereof into shares of Preferred Stock as
provided in this paragraph 11 at any time or from time to time prior to its expiration. Upon exercise 

  
 -7-

 
of the Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the holder of this Warrant,
without payment by the holder of any exercise price or any cash or other consideration, that number of shares of Preferred Stock equal to the quotient obtained by dividing the Net Value (as hereinafter defined) of the Converted Warrant Shares by the
fair market value (as defined in paragraph (c) below) of a single share of Preferred Stock, determined in each case as of the Conversion Date (as hereinafter defined). The “Net Value” of the Converted Warrant Shares shall be
determined by subtracting the aggregate warrant purchase price of the Converted Warrant Shares from the aggregate fair market value of the Converted Warrant Shares. Notwithstanding anything in this paragraph 11 to the contrary, the Conversion Right
cannot be exercised with respect to a number of Converted Warrant Shares having a Net Value below $100. No fractional shares shall be issuable upon exercise of the Conversion Right, and if the number of shares to be issued in accordance with the
foregoing formula is other than a whole number, the Company shall pay to the holder of this Warrant an amount in cash equal to the fair market value of the resulting fractional share. 

(b) The Conversion Right may be exercised by the holder of this Warrant by the surrender of this Warrant at the principal office of the
Company together with a written statement specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which are being surrendered (referred to in paragraph (a) above as
the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement, or on such later date as is specified therein (the
“Conversion Date”), but not later than the expiration date of this Warrant. Certificates for the shares of Preferred Stock issuable upon exercise of the Conversion Right, together with a check in payment of any fractional share and, in the
case of a partial exercise, a new warrant evidencing the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder of this Warrant within 15 days following the Conversion Date.

 (c) For purposes of this paragraph 11, the “fair market value” of a share of Preferred Stock as of a particular
date shall be its Market Price, calculated as described in paragraph 4(i) hereof (assuming for this purpose that references to “date of determination” (or words of similar import) in paragraph 4(i) shall be deemed references to
“Conversion Date”). 
 12. The Company will not, by amendment of its governing documents or through any
reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in
good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment. Without limiting the generality of the
foregoing, the Company (i) will not increase the par value of any shares issuable upon exercise of this Warrant above the amount payable therefor on such exercise, (ii) will take all such action as may be reasonably necessary or
appropriate in order that the Company may validly and legally issue fully paid and shares on the exercise of this Warrant, and (iii) will not close its shareholder books or records in any manner which interferes with the timely exercise of this
Warrant. 

  
 -8-

 13. All questions concerning this Warrant will be governed and interpreted and enforced in
accordance with the internal law, not the law of conflicts, of the State of Delaware. 

  
 -9-

 IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by its duly authorized
officer and this Warrant to be dated as of August 2, 2006. 
  

			
	LIPOSCIENCE, INC.
		
	By	 	/s/ Richard O. Brajer
		 	 Richard O. Brajer, President and Chief
 Executive Officer

 RESTRICTION ON TRANSFER 

“The securities evidenced hereby may not be transferred without (i) the opinion of counsel satisfactory to this corporation
that such transfer may be lawfully made without registration under the Federal Securities Act of 1933 and all applicable state securities laws or (ii) such registration.” 

  
 -10-

 SUBSCRIPTION FORM 
 To be Executed by the Holder of this Warrant if such Holder 
 Desires to Exercise
this Warrant in Whole or in Part: 
  

	To:	LipoScience, Inc. (the “Company”) 

 The undersigned
                                         
            
 Please insert Social Security or other 

identifying number of Subscriber: 
  

 
 hereby irrevocably elects to
exercise the right of purchase represented by this Warrant for, and to purchase thereunder,              shares of the Preferred Stock (the “Preferred Stock”) provided for
therein and tenders payment herewith to the order of the Company in the amount of $            , such payment being made as provided on the face of this Warrant. 

The undersigned hereby represents and warrants that the representations and warranties in paragraph 7 of the Warrant are true and correct
as of the date hereof. 
 The undersigned requests that certificates for such shares of Preferred Stock be issued as follows:

  

			
	 Name:
	 	 
		 	
	 Address:
	 	 
		 	
	 Deliver to:
	 	 
		 	
	 Address:
	 	 
		 	

 and, if such number of shares of Preferred Stock shall not be all the shares of Preferred Stock purchasable
hereunder, that a new Warrant for the balance remaining of the shares of Preferred Stock purchasable under this Warrant be registered in the name of, and delivered to, the undersigned at the address stated above. 

Dated: 
  

			
		
	Signature	 	  
		 	Note: The signature on this Subscription Form must correspond with the name as written upon the face of this Warrant in every particular, without alteration or enlargement or any
change whatever.

  
 -11-

 FORM OF ASSIGNMENT 
 (To Be Signed Only Upon Assignment) 
 FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto this Warrant, and appoints to transfer this Warrant on the books of the Company with the full power of substitution in the premises. 
 Dated: 
 In the presence of: 

 

	
	
	  
	(Signature must conform in all respects to the name of the holder as specified on the face of this Warrant without alteration, enlargement or any change whatsoever, and the
signature must be guaranteed in the usual manner)

  
 -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]